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Abstract 
REGULATION OF ANTI-THROMBOGENETIC FACTORS IN 
ENDOTHELIUM - prostacyclin, tissue plasminogen activator and 
plasminogen activator inhibitor type-1 
Hans E Rydholm, Department of Surgery, Sahlgrenska University Hospital, Östra, Göteborg, 
Sweden. 
Endothelial cells, producing both pro and anti-thrombogenetic substances are central to the 
cardiovascular system. A basic knowledge of the pathway which regulates the synthesis of 
the anti-thrombogenetic substances, prostacyclin (PGI2), tissue plasminogen activator (t-PA) 
and the fast inhibitor, plasminogen activator inhibitor type-1 (PAI-1), is crucial in order to 
modulate a dysfunctional endothelium in cardiovascular diseases. 
The aim of the present investigation was to clarify important aspects of the regulation of 
anti-thrombogetic factors in endothelial cells of different origin, in particular the influence of 
adrenergic control in PGI2 production and the regulation t-PA and PAI-1 production. 
Endothelial cells from human umbilical and adult great saphenous veins were harvested and 
cultured. The production of PGI2, t-PA and PAI-1 antigens were analyzed from the conditioned 
medium. The regulation of the cellular synthesis was studied by adding defined agonists or 
antagonists to receptors or intracellular transduction pathways. 
Adrenergic stimulation with isoprenalin increased PGI2 production from endothelial cells. The 
ß-adrenoceptor blocker, propranolol or metoprolol, increased the effect of isoprenalin, but had 
no effect per se. Different isomers of metoprolol with a high or low receptor blocking effect 
produced equal results. 
In dose-response studies, the production of t-PA and PAI-1 from umbilical and adult 
endothelial cells was increased by phorbolester or thrombin. At high concentrations, endotoxin 
also increased the production from umbilical but not from adult cells. Isoprenalin, ephedrine or 
endothelin-1 had no influence. Forskolin decreased the production of PAI-1, and Na-
nitroprusside increased it slightly. Neither of these substances influenced t-PA production. 
In "cross-talking" studies, the production of t-PA and PAI-1 could be modulated by co-
incubating different substances. The protein kinase C inhibitor H7 decreased the t-PA and PAI-
1 production augmented by endotoxin, thrombin and phorbolester, indicating an on-going 
signal transduction. Combinations with forskolin generally decreased agonist-induced PAI-1 
production. The effect on t-PA production diverged between umbilical and adult cells when 
endotoxin, thrombin or phorbolester were co-incubated with forskolin. 
In transduction studies, the thrombin-induced t-PA and PAI-1 production from adult 
endothelial cells was decreased by pertussis toxin or genistein, representing Gaj-protein and 
tyrosine kinase pathway inhibitors respectively. 
In conclusion: The production of prostacyclin from endothelial cells is under adrenergic 
control, modulating the effect of ß-adrenoceptor blockers. Signal transduction through adenylate 
cyclase, protein kinase C and tyrosine kinase pathways is critical in the regulation of t-PA and 
PAI-1 production from endothelial cells. Interference with these systems can be one way of 
modulating the balance between coagulation and fibrinolysis in the blood vessel. Endothelial 
cells of different origin regulate the production of t-PA and PAI-1 differently. 
Key words: endothelium, epoprostenol, b-adrenoceptor, plasminogen activator, 
plasminogen activator inhibitor, signal transduction, tyrosine kinase, GTP-binding protein, cell 
origin. 
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INTRODUCTION 
The primary function of the cardiovascular system is to distribute and exchange 
dissolved substances and mobile cells between different parts of the body. At the 
same time, the system must be able to react to local trauma, protecting the individual 
from life-threatening bleeding by closing parts of the system. These contradictory 
demand have created many interacting control systems regulating the fluidity of the 
blood. Unfavourable shifts in this balance will appear as cardiovascular disturbances, 
which is an important causes of morbidity and mortality. 
Endothelial cells (EC), with their unique position between the blood and the tissue, 
and their high production of regulatory substances, are central to the cardiovascular 
system. In the normal, uninjured state, the vascular surface is anti-thrombotic, but it 
could become pro-thrombotic if pertuburated. This anti-thrombotic function of EC is 
based on the production of nitric oxide (NQ= endothelium-derived relaxing factor, 
EDRF) (Moncada 1990), prostacyclin PGI2, (Levin 1984), tissue plasminogen 
activator (Kooistra 1994), thrombomodulin (Dittman 1995) and heparin-like glycos-
aminoglycans (Lindblom 1991). Several other factors produced and expressed by 
EC could act either pro- or anti-thrombotically (Borsum 1991, Risberg 1996). Many 
complex feedback mechanisms exist, adjusting local vasotonus and platelet aggre­
gation (Vane 1990, Lüscher 1990, Marcus 1993). Basic knowledge of the pathways 
which regulate the synthesis of thrombogenetic and non-thrombogenetic substances 
is crucial when trying to modulate the dysfunctional endothelium in cardiovascular 
diseases. This thesis focuses on the endothelial synthesis of the non-thrombogenetic 
substances: prostacyclin (PGI2), tissue plasminogen activator (t-PA) and 
plasminogen activator inhibitor type-1 (PAI-1). 
The final release of substances from endothelial cells is the integrated sum of 
multiple intra- and extra-cellular interactions. Regulating signals come to the cell 
surface from both substances in plasma blood-borne cells and also from the tissue 
beneath the cell. Several signal transduction pathways could interact intracellularly, 
modulating the external signals before they reach the DNA promotor (Liscovitch 
1992, Walsh 1994, Hill 1995, Post 1996). This rather complex picture requires an 
overview of: 1) endothelial interactions with other cells and plasma, 2) prostacyclin, 
extracellular influence, 3) coagulation, 4) fibrinolysis, extracellular influence, 5) 
intracellular signal transduction. 
Endothelial interactions 
The endothelial cell has an unique position between the blood and the tissue 
interacting with several different types of cells and soluble substances. Signals from 
platelets, leukocytes, erythrocytes and flow on the apical side and extracellular 
matrix and smooth muscle cells on the basal side are integrated. The principles of 
these interactions are reviewed in the following section. 
Platelets 
Platelets, being the first to react in the primary hemostasis could interact with the 
endothelial cells in a variety of ways. The sequence leading to a platelet thrombi will 
be reviewed in the coagulation section. 
The uninjured endothelium close to the aggregating platelet could regulate the 
spreading of the thrombi by producing prostacyclin (PGI2), 13-HODE, nitric oxide 
(NO) and expressing ADPase activity. PGI2 binds an adenylate cyclase-linked 
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platelets receptor, decreasing intracellular: Ca++, phospholipase C (PLC), and protein 
kinase C (PKC) activity, NO diffusing through the platelet membrane increases cyclic 
GMP (cGMP). PGI2 and NO could act synergistically, decreasing thromboxane 
production, cytoskeleton contraction and the occurrence of GPIIb/llla on the 
cellsurface. ADPases on the surface of endothelial cells metabolizes pro-aggregating 
ADP to anti-aggregating adenosin (Kroll 1989, Marcus 1993). 
On the other hand, pertuburated endothelium could produce the platelet-
aggregating factor (PAF), vWF and GPIIb/llla integrin, increasing platelet adhesion 
and aggregation (Wu 1995, Risberg 1996). 
Leukocytes 
The specific function of the leukocytes is to recognize and react to "foreign" 
substances. The endothelium is an active "middleman", transducting messages from 
the tissue to the leukocytes and guiding the immune-competent blood cells into the 
affected tissue. 
Leukocytes are first captured to "roll" on the endothelial surface by a family of 
adhesion molecules named selectines. By further interaction between integrins on 
activated leukocytes and cytokin-induced adhesion molecules (ICAMs) on endo­
thelium, the leukocytes become firmly attached (Bevilacqua 1993, Tedder 1995). 
Adhered neutrophils could degranulate at the endothelial surface, creating severe 
injuries, or migrate towards a chemo-attractant stimulus through the endothelial line 
into the tissue (Bratt 1995). 
Endothelial cells harbour P-selectins in Weibel-Palade granule and could express 
this transient selectin only minutes after being stimulated by thrombin or leuko-
trienes. Simultaneously-produced PAF activates leukocyte integrins. Cytokines (IL-1, 
TNFa, IL-8) from activated tissue or blood macrophages bind to specific receptors 
on the endothelial cells. On being thus stimulated, the endothelium, after a lag-
phase, will express the more long-lasting E-selectin and several types of immuno­
globulin adhesion molecules (ICAM, VCAM) that could interact with specific counter­
parts on blood leukocytes (Collins 1995). Endothelial cells could also down-regulate 
the effects of adhesion molecules and cytokins by producing inactivating soluble 
receptors that could bind to and inactivate their counterparts (Bonfari 1989, Tedder 
1995). Endothelial cells could also act as antigen-presenting cells interacting with 
T-helper cells to activate B and killer cells (Libby 1991). 
Erythrocytes 
Red blood cells incorporated in an early thrombi have been demonstrated to be 
prothrombotic, probably by interfering with adenosin and the NO metabolism (Marcus 
1993). 
Flow - Sheer stress 
Sheer stress could modulate several endothelial celi functions and structure by 
influencing GTP-binding proteins (Berthiaume 1992), intracellular Ca-n-, K+ (Olsen 
1988) concentration and tyrosine kinase activity (Berk 1995). Flow could rearrange 
cellular morphology, increasing prostacyclin (Brunkwall 1988, Berthiaume 1992), 
nitric oxide (Berk 1995), endothelin (Lücher 1990), t-PA (Diamond 1989) and proteo­
glycan production (Grimm 1988), thus this will creating a balance between vessel-
dilating flow and contracting tension. 
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Smooth muscle cells (SMC) 
Smooth muscle cette (SMC), in their contractile phenotype, are responsible for the 
vascular tone. Following vascular injuries with collagen net disruption and growth 
factor exposition, SMC could change into a synthesizing and migrating phenotype 
(Leeuwen 1996), 
Endothelial cells produce several substances that could modify the activity of SMC 
myosin light chain kinase and contraction by interfering with the SMC intracellular 
Ca++ distribution. Nitric oxide (NO) and prostacyclin (PGI2) could relax, whereas 
endothelin (ET) and some cyclooxygenase products (5.6-EET) could contract SMC 
(Lüsher 1990, 1992, Vane 1990). The endothelially-produced, platelet-derived 
growth factor (PDGF) and endothelin have a proliferating influence, whereas nitric 
oxide, prostacyclin, TGFß and heparan sulphate have a growth-inhibiting influence 
on SMC (Busse 1993, Fager 1995). 
Extra cellular-matrix (ECM) 
The extra-cellular matrix (ECM) is a complex dynamic structure interacting with the 
surrounding cells. In principal, ECM is build of collagen, glycoproteins such as 
fibronectin, lamelin, vitronectin and heparin-like proteoglycans (Ruoslahti 1985). The 
glycoproteins could be bonded to specific receptors on the surface of the endothelial 
cells. These receptors, mainly located to the basal cell surface, could be regulated as 
regards positioning and timing by the cell. Ligand-receptor interaction further initiates 
tyrosine kinase activity at focal adhesions (FAK) and signal transduction to the 
nucleus (Buchanan 1993, Moolenaar 1995, Erpel 1995). The composition of the 
matrix could influence the endothelial phenotype and the shape and production of 
substances such as t-PA, PAI-1 and PGI2, through this pathway (Gillis 1996). 
The ECM is also a storage for several cellular-produced and/or interacting 
substances such as vWF (Wu 1995), bFGF (Hawker 1994), plasminogen (Hajjar 
1986), active PAI-1 (Schleef 1990), latent TGFß and tissue inhibitors of 
metalloproteinases (TIMP's) (Magnatti 1993, Leeuwen 1996). 
Erythrocytes"" jf Leukocytes ) 
vWF PAF NO PGI2 Flow - Sheer 
ADPase 
("Smooth Muscle CellsF-~^i; Smooth Muscle Cells 2 
Endothelial cell Endothelial cell 
Éxtra cellular matrix 
P- / E-Selectins, 
ICAM. VCAM 
Endothelial cell : : 
Fig-1 Endothelial interactions. Summary, corresponding to the text in this section. 
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Prostacyclin 
Endothelial cells (EC), produce high quantities of prostacyclin (PGI2), an 
eicosanoid in the prostaglandin family. In contrast to nitric oxide, this lipid metabolite 
is not produced constitutively but as a result of endothelial stimulation. PGI2 has a 
short half-life with effect in the local vessel in synergy with nitric oxide. In the vascular 
lumen, PGI2, binding a specific platelet receptor, could decrease the tendency of 
platelets aggregation and at high concentrations even prevent adhesion. In the 
vascular wall, PGI2 relaxes smooth muscle cells (SMC) by interacting with their Ca++ 
flux. Prolonged prostacyclin exposition has even been found to prevent SMC 
hypertrophy (Levin 1984, Dusting 1990, Lüscher 1990, Vane 1990, Uehara 1991). 
Phospholipase Å2 - Arachidonic acid 
Phospholipids in the cell membrane are cleaved, preferably by the enzyme 
phospholipase A2 (PLA2 ), to produce arachidonic acid. This enzyme is important but 
also potentially destructive for the cell and has to be strictly regulated. The organism, 
in a complex system with many potential steps to regulate, produces different 
eicosanoids. Starting from arachidonic acid, different prostaglandins are produced 
locally in a consecutive series of enzyme reactions according to which tissue-specific 
enzymes are available (Liscovitch 1992, Dusting 1990, Roberts 1996). (See below). 
Agonist-regulated PGI2 production 
The production of PGI2 from endothelial cells in response to extra-cellular stimuli 
has been studied extensively. In cell-culture systems, increased synthesis has been 
reported for: thrombin, histamine (Jaffe 1987, Garcia 1991, Weigel 1991), bradykinin, 
leukotrienes (Clark 1986), endotoxin, PMA (Nawroth 1984), TNFa, IL-1 (Kawakami 
1986), interferon (Eldor 1984), complement (Suttorp 1987), endothelin (Vane 1990, 
Busse 1993) and shear stress (Frangos 1985). Inhibitory effects have been reported 
for: salicylic acid, non-steroid anti-inflammatory drugs (NSAID) (Gerritsen 1996), 
steroids (de Caterina 1986), growth factors (Chung-Welch 1988), hypoxia (Madden 
1986), and radiation (Eldor 1987). 
Prostacyclin, Hypertension, Adrenergic tonus 
A triad of low prostacyclin production, hypertension and high adrenergic tonus has 
been reported in various studies - in vivo on humans (Beckmann 1988) and rabbits 
(Åblad 1988), and in vitro on isolated guinea pig hearts (Löbel 1985) and rat aortas 
(Nishimiya 1990, Hiriwa 1991). These studies supported the hypothesis that 
decreased prostacyclin production could be a pathophysiological adaptation to the 
(over-)active adrenergic system and an etiologic factor in hypertension. 
The weakest link in this hypothesis is the lack of explanation as to how adrenergic 
stimuli could influence prostacyclin production from endothelial cells. Some authors 
have studied this subject using thrombin- or ionofor-stimulated cells (Adler 1981, 
Brotherton 1982, Hong 1983, Whorton 1985) or chloalose-treated rabbits (Pettersson 
1991). The cellular basis for the regulation is not yet completely understood. 
In the present study (paper I), using an non-stimulated experimental model, we 
have tested the hypothesis that prostacyclin production is regulated by adrenergic 
mechanisms. 
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Coagulation 
The blood clot 
The blood clot is a complex structure comprising a fibrin net-structure, adherent 
platelets and other blood cells. The ciot is in a state of permanent turnover creating a 
dynamic balance with the local environment. Interaction occurs with the fluid and 
cellular phases of the blood and also with the injured tissue and living cells of the 
vessel wall (Mosseson 1990, Marcus 1993, Blombäck 1996, Handt 1996). 
The coagulation cascade 
The fibrin net is the final product in a long series of proteolytic enzymes -the 
coagulation cascade. In the blood, all the coagulation factors exist in very low 
concentrations and to be able to react in vivo, they have to be brought together, 
bound to specific surfaces. Phospholipids in the platelets or endothelial cell 
membrane could act as binding surfaces. 
There are mainly two ways to start the coagulation cascade. These are the 
"internal" and the "external" pathways. In vivo, the "external" pathway seems to be 
the most important. The "internal" pathway, starting with the activation of factor XII by 
collagen or matrix proteins, is probably less powerful (Roberts 1995). The critical 
step in the initiation of the "external" pathway is the expression of a specific 
lipoprotein named Tissue Factor (TF). TF is produced by many activated cell types 
including endothelial cells, macrophages, monocytes, foam cells. TF is also bound to 
the cellular surface, the subcellular matrix and to the central cores of atherosclerotic 
plaque. TF can complex-bind coagulation factor VII, the binding de-conformates the 
molecule and dramatically increases the enzyme activity (Camerer 1995). 
The final activator in the coagulation cascade is thrombin, an enzyme with a broad 
substrate specificity. Thrombin, by cutting off two polypeptides, polymerises 
fibrinogen into long fibrin filaments. Simultaneously, thrombin activates factor XIII 
that further degrades and uncovers cross-linking sites on fibrin filaments, completing 
the fibrin net structure (Mosseson 1990, Blombäck 1996). 
Regulatory feedback mechanisms 
There are several regulatory feedback systems in the coagulation cascade 
(Roberts 1995). The formation of fibrin could be inhibited by: 
a) antithrombin III (ATIII), a liver-synthesized serine proteinase inhibitor. ATIII, in 
complex with heparin-like glycosaminoglycans on the surface of endothelial 
cells, inactivates several coagulation factors including factors Xa, IXa, Xla, XIla 
and thrombin. 
b) thrombin in complex with endothelial surface-bound thrombomodulin could 
bring Protein C and S together, creating Activated Protein C (APC). This 
proteolytic enzyme cleaves and inactivates the coagulation factors Va and 
Villa. APC could also bind and inactivate PAI-1, stimulating fibrinolysis 
(Krishnamurti 1992, Dittman 1995). 
c) the rate-limiting step in the "external" coagulation cascade, the tissue factor in 
complex with FVll. could be effectively inhibited by activated factor X in 
complex with the tissue factor pathway inhibitor (TFPI or EPI). Endothelial cells 
and platelets (megakaryocytes) are the source of TFPI (Camerer 1995, 
Petersen 1995). 
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Endothelium-Coagulation 
The endothelial cell, being either pro- or anticoagulant, has a central and pivotal 
role in the dynamic turnover of the blood clot (Risberg 1996). 
Procoagulant endothelium 
When perturburated the endothelium could initiate coagulation, platelets / 
leukocyte adhesion and vascular smooth muscle contraction. The procoagulative 
state is created by the appearance of the tissue factor and adhesion molecules such 
as integrins (GPIIb/llla, vitronectin receptor), selectins (P-, E-selektin), and the Ig-
superfamily (ICAM, VCAM) on the cell surface. Thrombosis formation is also facilit­
ated by the endothelial secretion of the von Willebrant factor (vWF), factor VIII, P-
selectin, plasminogen activator inhibitor type 1 (PAI-1), platelets activation factor 
(PAF) and endothelin (ET) (Borsum 1991, Bevilacqua 1993, Buchanan 1993, Wu 
1995). 
Anticoagulant endotheSium 
The endothelium could reduce the growth of the fibrin clot, counteracting platelets 
aggregation / adhesion and promoting vascular smooth muscle relaxation. The anti-
coagulativ state is created by the expression of heparin-like glycosaminoglycans and 
thrombomodulin on the cell surface. Further secretion of nitric oxide, prostacyclin, 
13-HODE, TFPI and t-PA acts as an anticoagulant (Moncada 1990, Borsum 1991, 
Buchanan 1993, Kooistra 1994, Petersen 1995, Dittman 1995). 
Platelets-Coagulation 
Platelets adhere / aggregate and initiate vascular constriction in the primary 
hemostasis and also by interacting with the coagulation cascade and the endo­
thelium co-operate in the creation of a fibrin-stabilised thrombi. When exposed to the 
blood in injured tissue, vWF bound into the sub-endothelium could adhere and 
activate platelets (Wu 1995). The activated platelets release coagulation factors, 
serotonin, ADP, Ca^ and PAI-1. They also start to produce thromboxan. 
Simultaneously, coagulation binding surfaces and aggregating integrins (GPIIb/llla) 
will be exposed on the platelet surface. Coagulation factors will be bound and active 
on the platelet surface, producing thrombin and creating a positive feedback loop. 
Fibrinogen and vWF molecules could bind surface integrins and promote platelets 
aggregation (Marcus 1993). Platelets-bound PAI-1, although mostly in the latent 
phase, could protect the thrombi from lysis (Declerch 1988, Handt 1996, Robbie 
1996). By expressing P-selectin and secreting chemotactic substances such as 12-
HETE, activated platelets could attract neutrophils to be built into the thrombi. 
Neutrophils have antiplatelet-aggregating and thrombolytic potential but also induce 
inflammatory reaction by secreting leucotriens (LTB4). Red blood cells incorporated 
in the fibrin net are prothrombotic probably by interfering with adenosin, NO 
metabolism (Marcus 1993, Soo 1996). 
Fibrinolysis 
General schemes 
Fibrinolysis has revealed itself to be a central biological mechanism involved not 
only in vessel wall anti-thrombogenicity, but also in cellular migration processes such 
as angiogenesis or malignancy (Pepper 1993, Blasi 1993, Mignatti 1993, Leeuwen 
1996). The balance between coagulation and fibrinolysis plays a pivotal role in the 
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regulation of the fibrin clot. Disturbances in blood fibrinolytic parameters have been 
associated with myocardial infarction and identified as an important prognostic risk 
factor for several neoplasms (Hamsten 1993, Brünner 1994, Juhan-Vague 1996). 
Accordingly deep vein thrombosis epidemiological studies have presented diverging 
results, probably due both to methodological difficulties and the great variety of 
interacting factors (Eriksson 1991, Takada 1994, Wiman 1995). 
Many different types of cells could produce proteins that influence the fibrinolytic 
balance (Hart 1988, Loskutoff 1989, Kooistra 1990). Owing to their location between 
the blood and the tissue and their high production of t-PA, u-PA, and PAI-1, endo­
thelial cells are central to vascular fibrinolysis and angiogenesis (v Hinsbergh 1987, 
Kooistra 1994). 
Plasmin 
Plasmin, the potent proteolytic enzyme, is the active principal in the fibrinolytic 
system. Active plasmin degrades not only fibrin but also proteins in the extracellular 
matrix (Mignatti 1993, v Leeuwen 1996) and cell receptors (Schäfer 1987). Plasmin 
could also activate single-chain t-PA / u-PA, latent TGFß, latent collagenase, and 
release bFGF from the matrix (Mignatti 1993, Plow 1995, v Leeuwen 1996). This 
rather non-selective proteolytic potential has to be strictly controlled by the organism 
both as regards positioning and timing. 
a2-antiplasmin 
With a half-life of about 1 second, free active plasmin is inactivated by proteinas 
inhibitors. The most important inhibitor has revealed itself to be a2-antiplasmin while 
«2-macroglobulin and «1 -antitrypsin are much less effective (Collen 1991). a2-anti-
plasmin is a glycoprotein produced by the liver with a Mr of about 70 000 and a half-
life of 2-3 days. This inhibitor, belonging to the serpin family, catches plasmin in a 
two-step reaction, where the first lysine-binding step could be inhibited by fibrin or 6-
aminohexanoic acid (6-AHA) (Collen 1991). a2-antiplasmin is also incorporated in 
the fibrin clot, preventing premature plasmin lysis (v Giezen 1993). 
Plasminogen activation 
Plasminogen (Pig) is a 92 000 Mr glycoprotein with a half-life of about 3 days, 
synthesized by the liver (Collen 1991). Through the lysine-binding sites in the 
"kringle" domains, it could be linked to fibrin, cell surfaces or the extracellular matrix 
(Rånby 1982, Hajjar 1986, Knudsen 1986, Redlitz 1995). Pig is a circulating pro­
enzyme that could be cleaved and converted to active plasmin by plasminogen 
activators (PA). The most important PA's are tissue plasminogen activator (t-PA) and 
urokinase (u-PA). Owing to its different characteristics, t-PA seems to be the 
predominating PA in plasma, and u-PA is the most active PA in the tissue (Rijken 
1995). However, results from gene knock-out experiments, have indicated that t-PA 
and u-PA could be exchangeable (Carmeliet 1995, Lijnen 1996). 
Plasminogen activator inhibitors 
Plasminogen activator inhibitors (PAI's) act as specific substrates for t-PA or 
u-PA, rapidly creating inactive complexes (Hekman 1988, Loskutoff 1989). Several 
types of PAI exist. Normally, PAI-1 seems to be the most important inhibitor in 
plasma. The role of PAI-2 is more controversial, probably having more tissue and 
intracellular functions (Dear 1995, Rijken 1995). Other inhibitors such as a2-macro-
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globulin, C1-inhibitor, PAI-3 (APC inhibitor) and a2-antiplasmin are much less 
effective, probably having an effect only during pharmacological thrombolysis 
(Sprengers 1987, Chandler 1996), 
Therapeutically-added streptokinase forms a stable non-inhibitory complex with 
plasminogen (a half-life of about 25 minutes) and creates large amounts of plasmin 
(Collen 1991). 
The fibrinolytic system 
The net fibrinolytic activity is a function of production, complex formation and 
clearance of PA and PAI-1 respectively. In the small peripheral vessel, the activity is 
also determined by the local blood flow. The fibrinolytic system is carefully restricted 
by the regulation of the synthesis, release, activation, localization and inhibition of 
the participating substances (Chandler 1996). 
Gene knock-out experiments have demonstrated that substances in the fibrinolytic 
cascade could be exchanged. Single knock-out of u-PA or t-PA presented increased 
thrombus formation only when pertuburated, whereas double knock-out u-PA + t-PA 
or single knock-out of plasminogen or genes expressing high PAI-1 all demonstrated 
spontaneous thrombosis. On the other hand, PAI-1 knock-out produced bleeding and 
the incapacity to form thrombi. Even neo-intima formation could be influenced by 
gene knock-out showing u-PA important activator and PAI-1 to be an inhibitor of 
cellular migration (Carmeliet 1995, Lijnen 1996). 
In the following section, the single substances taking part in the fibrinolytic system, 
t-PA, u-PA, PAI-1, PAI-2 and non-specific activators and inhibitors, will be presented. 
Interactions with fibrin, complex formation and clearance will be discussed at the end 
of this section. 
TFPI 
t 
Coagulation 
Kallikrein 
FXII 
Tissue factor 
AT III 
APC Thrombin 
Fibrinolysis 
Plasminogen 
• t-PA X3=: PAI-1 
Plasmin cc2-anti plasmin 
Fibrinogen Fibrin FDP 
Fig. 2 Schematic figure of coagulation and fibrinolysis. 
Tissue plasminogen activator (t-PA) 
A glycoprotein with Mr of 65 000, belongs to the serine protease family. Kringle 
and finger domains in the molecule give t-PA specific fibrin affinity. t-PA is secreted 
primarily by endothelial cells although synthesis has also been demonstrated by 
macrophages, mesothelium and various tumourcells (Risberg 1986, Hinsbergh 
1987, Hart 1988, Falkenberg 1996). Consequently, the capillary bed, representing a 
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huge endothelial surface of about 1000 m2 is the main source of t-PA (Chandler 
1991, 1996, Schrauwen 1994). 
t-PA is released from the oeil as a single-chain molecule (sct-PA). Plasmin could 
cleave and convert single-chain to two-chain t-PA (tct-PA). As they have different 
kinetics, both sct-PA and tct-PA are active plasminogen activators (Rånby 1982, 
Kluft 1994, Rijken 1995). t-PA could be bound both to fibrin (as will be discussed 
later) and to cell surfaces. At the celt membrane, t-PA effectively activates surface-
bound plasminogen to plasmin. Furthermore, surface t-PA and plasmin have been 
demonstrated to be protected from inactivation by PAI and a2-antiplasmin 
respectively. Consequently, high local fibrinolytic activity could be maintained at the 
surface (Haijjar-86, Bu 1994, Plow 1995, Redlitz 1995). 
Release / Regulation, t-PA 
Two types of stimulated cellular t-PA release have been described; a) a rapid -
short and b) a slow - continuous release (Tranquille 1990, Kooistra 1994). In vitro, 
the rapid t-PA release has been demonstrated to be proportional to the slower new-
synthesis release (v Eijnden-Schrauwen 1995). In contrast to PAI-1, t-PA 
demonstrates only a weak circadian variation and a limited acute-phase protein 
response (Chandlerl 991). 
a) The rapid, albeit limited, release originates from pre-synthesized, cell-stored 
t-PA (Tranquille 1989). Endothelial cells could bind t-PA on their surfaces (Redlitz 
1995, Cheng 1996), but even intracellular storage vesicles have been predicted 
(Kooistra 1994). Probably, separate pools with different regulation exist, as the post­
release desensitization has revealed itself to be substance-specific (Kooistra 1990). 
in vitro, the cellular pools have been demonstrated to be quite small, but there are 
indications that they could contain much more t-PA in vivo (Tranquille 1989, Padrö 
1990, Giles 1990, v Eijnden-Schrauwen 1995). The rapid release could be induced 
by agonists connected to the protein kinase C /Ca++ system such as thrombin, 
histamine, substance P, endothelin, bradykinin, epinephrine and PAF (Zhu 1989, 
Tranquille 1990, Chandler 1992, Kooistra 1994, Jem 1994). Cyclic nucleotides 
(cAMP, cGMP) could modulate but not induce acute release (Tranquille 1993). t-PA 
increased by exercise, is induced by a combination of epinephrine-increased 
release and a decreased hepatic clearance (Chandler 1993). 
b) The slower but quantitatively larger t-PA release from the endothelium has 
been found to be preceded by a lag-phase of protein synthesis. Consequently, this 
release could be controlled at the transcription and translation levels. Several 
substances have been demonstrated to increase this synthesis-dependent release: 
thrombin and histamine (Hanss 1987, Dichek 1989, Francis 1989, Grülich-Henn 
1990), retinoids (Kooistra 1994), sheer stress (Diamond 1989, Iba 1991) and lipids 
such as butyrate (Kooistra 1987). On the other hand, no effect has been observed 
following exposure to endotoxin or cytokines (Bevilacqua 1986, Hanss 1987, Schleef 
1988). In human endothelium, neither steroids nor bFGF have proved to have any 
effect on t-PA production (Kooistra 1994). 
Urokinase (u-PA) 
Urokinase is a glycosylated serine protease with a Mr of about 54 000. Compared 
with t-PA, the molecule, contains only one kringle and no finger domain and, 
consequently, has no fibrin specificity. u-PA is secreted from the cell as a inactive 
single-chain molecule scu-PA. Plasmin, kallikrein, or FXIIa could cleave scu-PA and 
create active two-chain tcu-PA. Only the active tcu-PA could rapidly form an 
inactivating complex with PAI-1 or PAI-2. tcu-PA is also inactivated, but at a much 
- 9 -
lower rate, by a2-antiplasmin, a2-macröglobulin and C1-inhibitor. In plasma, the half-
life of tcu-PA is about 8 minutes and almost all the u-PA is in the non-inhibited, non-
active scu-PA form. u-PA production has been reported from several different cell 
types: endothelium, fibroblast, smooth muscle cells, epithelial cells, pneumocyter, 
trophobasts, monocytes and various tumour cells (Hart 1988, Duffy 1993, Vassalli 
1994, Dana 1994, Rijken 1995). In the non-perturburated state, in vitro u-PA has 
been found only in the kidney and lung tissue (Quax 1990). 
uPA production could be increased by several factors, interacting both transcrip­
tionally and post-transcriptionally (Bessner 1996). Growth factors, phorbolester, 
cytokines and coagulation factor such as thrombin have all been demonstrated to 
increase u-PA (Pepper 1993, Blasi 1993, v Hinsbergh 1994, Gualandris 1995). 
Several cells have specialised u-PA receptors (u-PAR) on their surfaces. The 
receptor binds the EGF domain on single- or two-chain u-PA. Inactive scu-PA could 
be converted to tcu-PA at a much higher rate when bound to the receptor. u-PAR-
bound u-PA could rapidly cleave cell-bound plasminogen into active cell-bound 
plasmin. The cell could regulate the position and affinity of u-PAR on its surface and 
also determine when this should happen. This ability could create a migrating, 
invasive potential. Many tumour cells express u-PAR on their own surfaces but 
stimulate other stroma cells to produce u-PA (Blasi 1993, 1994, Dane 1994). In 
general, the u-PAR is upregulated by cytokines, TGFß, phorbolester, bFGF (Pepper 
1993, Blasi 1994, Vassalli 1994, Lund 1995, Bessner 1996). In contrast to t-PA, cell-
bound tcu-PA could be inactivated by PA1-1 or PAI-2. The inactive tcu-PA/PAl /u-
PAR complex is internalized into the cell by the low-density lipoprotein (LDL) 
receptor-related protein (LRP). The complex is fragmented and the receptor could re­
cycle to the surface (Blasi 1993, Strickland 1994). 
Other fibrinolytic activators 
The contact phase of coagulation represented by factor XII and kallikrein could 
contribute to fibrinolysis. This pathway is named "the intrinsic activation". The activity 
is generated through several routes: kallikrein could convert scu-PA to tcu-PA that 
will release bradykinin or kallikrein could also activate an non-identified plasminogen 
activator. The physiological importance of this system is probably very limited. The 
effect has been demonstrated only at massive activation of the contact system using 
extra corporal circulation or at C1-esterase inhibitor deficiency (Binnema 1990, Kluft 
1994, Rijken 1995, Chandler 1996). 
Transgenic animals with a double knock-out of both t-PA and u-PA or single 
knock-out affecting plasminogen could develop and survive. These data call upon 
the existence of other non-plasmin-mediated fibrinolytic principles (Carmeliet 1995). 
Matrix metalloproteinaser (MMP), normally interacting with plasmin in basal lamina 
degradation, could be an alternative fibrinolytic pathway (Lijnen 1996, v Leeuwen 
1996). By secretion of elastase and cathepsin G, polymorphnucleated neutrophils 
and macrophages could also create a non-plasmin fibrinolysis (Magnatti 1993, Soo 
1996). 
Plasminogen activator inhibitor type-1 (PAI-1) 
Plasminogen activator inhibitor type-1 (PAI-1) is a glycoprotein in the serpin 
inhibitor family with Mr 52 000. PAI-1 is a fast inhibitor of sct-PA, tct-PA and tcu-PA 
but not of scu-PA (Sprengers 1987, Hart 1988, Loskutoff 1989, Krishnamurti 1992). 
PAI-1 has been demonstrated to be secreted from several types of cell including 
endothelial cells, hepatocytes, smooth muscle cells, fibroblasts, endometrial cells, 
synovial cells, adiposal cells and megakaryocytes (Loskutoff 1989, Krishnamurti 
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1992, Thornton 1995). There has been diverging data demonstrating the source of 
PAi-1 in vivo. Freshly-harvested endothelial cells produce low levels of PAi-1, which 
rise considerably when cultured (vd Berg 1988). The production of PAI-1 in vitro 
seems to be much higher than the calculated production in vivo (Chandler 1996). A 
substantia! PAI-1 secretion has been measured over the hepatic circulation 
(Brammer 1988), compared with only a small release over the peripheral capillary 
bed (Kreb 1990, Jern 1994). On the other hand, immunological and in situ hybrid­
isation methods have shown PAI-1 to be co-localised with endothelial cells through­
out the entire body (Loskutoff 1991, Simpson 1991, Keeton 1993, Falkenberg 1996). 
In vitro PAi-1 production from endothelium was found to decrease when co-cultured 
with smooth muscle ceils (Christ 1992). To sum up, the in vitro situation probably 
represents a state of non-specific upregulation. 
Active - Latent PAI-1, Vitronectin 
PAI-1 is secreted from the cell as an active glycosylated molecule. In a free-fluid 
phase, the active molecule, with a half-life of 2-3 hours, spontaneously undergoes 
tertiary conformation changes and becomes inactive "latent PAI-1". "Latent PAI-1" 
could be reactivated under laboratory conditions. However, in vivo, "latent PAI-1" is 
thought to be in an irreversible inactive form (Levin 1986, Kooistra 1986, Lambers 
1987, Hekman 1988, Boström 1990). Platelets contain a great pool of PAI-1 thai will 
be liberated as the platelets de-granulate. A very high percentage of this 
megakaryocyte-synthesized and platelets-stored PAI-1 is in the latent inactive form. 
Nevertheless, platelet-rich clots are semi-resistant to t-PA induced fibrinolysis, 
probably because of PAI-1 activity from de-granulating platelets (Kruithof 1987, 
Declerch 1988, Simpson 1990, Handt 1996, Robbie 1996). 
Active PAI-1 binds to the liver synthesized macromolecule vitronectin. This binding 
stabilises the active form of the PAI-1 molecule. Vitronectin, binding PAI-1, exists 
both in plasma and as an integrated part of the extracellular matrix (Wiman 1988, 
Mimuro 1989a, 1989b). In vitro, the small matrix-bound active PAI-i pool (1-2 
ng/cm2) has been found to represent an exchangeable and potentially biologically 
active part of the matrix (Levin 1987, Mimuro 1987, 1989a, Schleef 1990, v Leeuwen 
1996). On the other hand, no acute PAI-1 release as for t-PA has been detected 
(Schleef 1988, Diamond 1989, Keber 1990, Jern 1994). Vitronectin could also form 
trimer-complexes with PAI-1 and thrombin or with heparin and thrombin. Complex 
formation significantly inhibits thrombin-induced APC activation (Rijken 1995). 
Release / Regulation, PAI-1 
After stimulation, a lag-phase of several hours with DNA transcription, translation 
and glucosylation precedes increased PAI-1 secretion from the cell (Laiho 1987, 
Schleef 1988, Medina 1989, Loskutoff 1991). Several substances have been 
reported as influencing the PAI-1 production in vitro: 
Phospholipase C, activated by substances such as thrombin and histamine 
(Gelehrter 1986, Hanss 1987, Dichek 1989, Francis 1989, Grulich-Henn 1990). 
Inflammatory mediators such as interleukin-1 (IL-1) (Median 1989, Beviliacqua 
1986, Schleef 1988) and tumor necrosis factor (TNFa) (vd Berg 1988, Median 1989, 
Sawdey 1989, v Hinsbergh 1990, 1994), an effect that could be potentiated by 
interferon-y (Amman 1995). Several studies have demonstrated that endotoxin (LPS) 
induces PAI-1 production. However, there have been great differences between 
reports from in vivo and in vitro experiments and also between sera and non-sera in 
vitro experiments (Colucci 1985, Hanss 1987, vd Berg 1988, Median 1989, Sawdey 
1989, 1991, Slivka 1991, Quax 1990). 
-  11  -
Growth factors such as transforming growth factor-beta (TGFß) have been 
reported by several authors to increase PAI-1 production (Laiho 1987, Keski-Oja 
1988, Sawdey 1989, Slivka 1991) and endothelial cell growth factor (ECGF) to 
decrease PAI-1 production (Konkie 1988). In vitro, hepatocytes, but not endothelial 
cells, increase PAI-1 production when exposed to insulin or corticosteroides 
(Rehmentulla 1987, Heaton 1989, loskutoff 1991). Matrix molecules underneath the 
cell could also influence PAI-1 production (Gillis 1995). 
Sheer stress and physical exercise increased t-PA but had no effect on PAI-1 
production (Diamond 1989, Chandler 1993). 
In epidemiological studies, increased levels of PAI-1 have been correlated to 
ageing, smoking, general arteriosclerosis including myocardial infarction, diabetes, 
malignancy, hyperiipidemi, server liver disease and pregnancy. It has also been 
suggested that polymorphism in the gene influences plasma PAI-1 levels (Hamsten 
1993, Takada 1994). 
In general, PAI-1 shows a circadian variation with the highest concentrations in 
the early morning. PAI-1 also acts as an acute-phase protein increasing after trauma, 
operations and sepsis. 
Plasminogen activator inhibitor type-2 (PAI-2) 
PAI-2, a serine proteinase inhibitor in the serpin family. The molecule exists in two 
forms; intracellular non-glycosylated with a Mr of about 46 000 and an extracellular 
glycosylated form with a Mr of about 70 000. PAI-2 is mainly an inhibitor of tcu-PA. 
Non-fibrin-bound tct-PA could also be inhibited but this effect is probably not physio­
logical (Åstedt 1985, 1987, Lecander 1986, Dear 1995). PAI-2 was initially isolated 
from placenta and plasma from pregnant women. It was demonstrated later to be 
produced from a wide range of cells. Monocytes, leukocytes, keratinocytes, 
granulosa cells, microglia, endothelium, and mesothelium cells all produce PAI-2. 
Several tumour cells secrete PAI-2 and, with some exceptions, a relationship 
between high PAI-2 levels and restricted metastatic potential has been found (Åstedt 
1985, 1987, Lecander 1986, Dear 1995). 
PAI-2 production is increased by cytokines (such as TNFa, IL1, IL-2), angiotensin 
II, phorbolester, and phosphatase inhibitors such as okadaic acid. Production is 
decreased by dexamethasone, retinoids, TGFß, IL-4 and modulated by cyclic AMP. 
This pattern of regulation indicates both G-protein, protein kinase C, and tyrosine 
kinase signal transduction. 
Extracellular PAI-2 could modify cell surface fibrinolysis and cellular migration. 
Being more resistant to oxidants than PAI-1, it may modulate inflammatory 
processes. The biological function of intracellular PAI-2 is still not quite clear. A role 
in differentiation, apoptosis and inflammatory response has been suggested. (Åstedt 
1985, 1987, Lecander 1986, Rijken 1995, Dear 1995). 
Other plasminogen activator inhibitors 
In physiological conditions, PAI-1 and PAI-2 are the principal inhibitors to 
plasminogen activators owing to the high constant rate in complex formation. There 
are several other substances with a much lower PA inhibitory potential: a2-macro-
globulin, C1 -inhibitor, a2-antiplasmin, PAI-3 (APC-inhibitor), antitrombin III and 
protease nexin 1. These substances could serve as a second line of inhibition if, for 
example the capacity of PAI-1 and PAI-2 becomes overloaded during thrombolysis 
therapy (Sprengers 1987, Hart 1988, Rijken 1995). 
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PA and PA1 interactions 
Fibrin interaction 
Both plasminogen and t-PA could be bound to fibrin. This fibrin co-binding 
increases t-PA conversion of plasminogen to plasmin approximately 200-400 times. 
Plasmin is also partially protected from cc2-antiplasmin inhibition when localised to 
the fibrin surface. Local plasmin proteolysis, in a positive feedback loop, further 
degrades Glu-plasminogen to Lys-plasminogen and single chain t-PA, u-PA to two-
chain t-PA, u-PA respectively. The fibrin specificity is performed by lysine bindings 
on the kringel and finger domains that exist on plasminogen, t-PA, and PAI-1, but not 
on the u-PA molecule. Consequently, the PAI-1 (even latent) and t-PA/PAI-1 
complex could compete with plasminogen and t-PA for these bindings. Further 
lysine-rich substances such as lipoprotein(a) or therapeutically-added tranexamic 
acid could block the bindings and thereby decrease fibrin adhesion and degradation 
(Rånby 1982, Mosesson 1990, Redlitz 1995, Blombäck 1996). The interaction 
between fibrin and u-PA is complicated. Partially plasmin-degraded fibrin exposed 
new binding sites for plasminogen. Bound plasminogen changes conformation and 
becomes attractive for scu-PA binding. scu-PA, still being inactive, could be cleaved 
and activated by plasmin (Fleury 1993, Chandler 1996). 
Endothelial cells that have been covered at their luminal surface with fibrin 
increase t-PA and decrease PAI-1 production (Fukao 1995). The cells also change 
phenotype into a synthesizing, migrating form (Kadish 1979, Soo 1996). Endothelial 
produced PAI-1 could has been demonstrated to infiltrate and delay fibrinolysis of 
fibrin clots in (Handt 1994, 1996). 
Complex formation / Clearance 
In the circulation, the fibrinolytic activity is mainly determined by the level of active 
t-PA. The free t-PA activity could be rapidly inhibited through complex formation, 
normally with PAI-1. In a two-phase reaction, t-PA (or tcu-PA) first binds to and then 
cleaves and becomes catched into an inactive 1:1 complex with the PAI molecule. 
The enzyme reaction between t-PA and PAI-1 has a very high rate constant, but as 
the concentrations of the substances in plasma are low, a steady state with a 
considerable amount of free active t-PA is created (Sprengers 1987, Hekman 1988). 
At a physiologically high PAI-1 concentration, (300 pmol/l) only 10% of plasma t-PA 
is active, rising to 20-50% free t-PA when the PAI-1 concentration is in the lower 
range (<100 pmol/l) (Chandler 1991). 
The hepatic clearance of t-PA, PAI-1 and the t-PA/PAl-1 complex is rather rapid 
owing to several different receptor mechanisms (Redlitz 1995). The elimination is a 
direct function of the hepatic blood flow. For the t-PA/PAI-1 complex, half-life is 
approximately 3-5 minutes. Free t-PA has an even faster hepatic elimination and 
also rapid PAI-1 inactivation in the circulation, giving a normal half-life of only about 1 
minute. The "hepatic" half-life of active PAI-1 is about 10 minutes and together with 
complex binding at normal t-PA levels gives a total half-life of about 5 minutes 
(Sprengers 1987, Brammer 1988, Chandler 1996). Disturbed hepatic elimination 
could influence the fibrinolytic activity in plasma. Hepatic dysfunction, such as 
cirrhosis or prolonged bile stasis, results in an increased fibrinolysis because of a 
combination of decreased t-PA clearance and reduced production of PAI-1 and 
«2-antiplasmin (Huber 1991). 
This section has summarized the fibrinolytic system. The regulation, turnover and 
proposed biological function of the substances involved in the cascade has been 
discussed. More about the intracellular regulation of fibrinolysis will be described in 
the corresponding parts in the result and discussion sections. 
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intracellular signal transduction 
An extracellular signal coming to the cell has to pass through the cellular 
membrane and continue through the integrating net of transducting pathways before 
the message finally reaches a specific intracellular effector system. 
A transmembrane receptor-protein transducts the signal through the cell 
membrane. Each receptor type is unique for a specific extracellular substance. When 
a receptor binds an agonist, the conformation of the receptor molecule is changed, 
uncovering new catalysing sites of the intracellular part. Depending on the type of 
catalytic activity and intracellular micro-environment, the receptor-signal could be 
linked to different transduction pathways. The transducting pathways are cascades 
of subsequent enzyme reactions bringing the signal to the effector system, being an 
enzyme system or a gene promotor region. Several points of interaction between the 
different pathways exists ("cross-talk"), modulating the original signal (Hausdorff 
1990, Brass 1993, Seger 1995, Post 1996). 
In the following section, parts of the signal transduction systems will be discussed. 
The presentation has been indexed in subdivisions: 
A) Main transduction pathways: 
1)The GTP-binding protein systems 
a) The adenylate cyclase system 
b) The phospholiphase C/D - protein kinase C system 
2) The mitogen-activated protein (MAP) kinase system 
B) General intracellular signai systems: 
1 ) Ca++ system 
2) Transcription factors 
C) Intracellular effector systems: 
1) The fast enzyme system, Arachidonic acid - Prostacyclin 
2) The slow gene-transcription system, t-PA and PAI-1 
Main transduction pathways 
GTP-binding protein systems 
Receptors linked to the adenylate cyclase or phospholiphase C/D system, belong 
to the seven transmembrane-spanning receptor family. These receptors transduct 
signals further through the membrane bond GTP-binding protein system. In the non-
activated state, the intracellular part of the receptor molecule is bound to a protein 
dimer, the ßy-subunit. Another protein, the a-subunit, is linked to the ßy-dimer, 
creating a trimer. The a-subunit could also bind GDP in this state. When the receptor 
is activated, it catalyses the a-subunit to release GDP and instead binds GTP. The 
GTP-bound a-subunit has low affinity for the ßy-dimer and dissociates. The ßy-
subunit is also now released from the receptor. The free a-unit or even high 
concentrations of the free ßy-dimer could interact with different intracellular enzymes. 
The active a-subunit is auto-inactivated, as GTP is hydrolysed to GDP; a reaction 
that could be increased in a negative feed back loop by several effector enzymes. 
After being hydrolysed to GDP the aßy-trimer could be reformed and be ready for 
new signals to be transducted. 
There are 22 different a-subunits, 7 different y-subunits and 4 different ß-subunits 
identified. Different types of subunit could induce different intracellular responses, 
creating an enormous potential of combinations. A single activated receptor could 
-  1 4 -
dissociate many a / ßy -subunits, sometimes even of different types. Hence the GTP-
binding protein system permits transduction, potentiation and diverging of the 
receptor signal (Hausdorff 1990, Birnbauer 1992, Hepler 1992, Bernstein 1992). 
Agonist 
Receptor 
T GDP 
GDP-Ga-ßy, GTP 
GDP-Ga-ßy 
GTP-Ga 
GDP 
GTP E + GTP-G, 
Product Precursor 
Fig 3. Receptors linked to the adenylate cyclase or phospholiphase C/D system, transduct 
signals through the membrane bond GTP-binding protein system to the effector system (E). 
The adenylate cyclase system 
Many cell-surface receptors, for example the ß-adrenoceptor activates GTP-
binding protein a-subunits of the s- type, Gas-protein. The «-adrenoceptor activates 
the God-protein by dissociating it from the ßy-dimer. Gas activates and G«i 
inactivates the membrane-bound enzyme adenylate cyclase (AC) (Sibley 1985, 
Hausdorff 1990, McEwan 1990). The effect of the free ßy-dimer could be different, 
depending on the cell-specific type of AC-isomer (Iyengar 1993, Manolopoulos 
1995b). Other non-AC-transducted functions have also been reported for the Gas 
/Gai /ßy units, although not completely characterized in endothelium (Barber 1989, 
Schubert 1989, Yatani 1989, Limbird 1990, Williams 1995). 
AC converts intracellular AMP to cyclic AMP (cAMP). cAMP activates protein 
kinase A (PKA). This is a kinase with several intracellular effector substrates. The C-
terminal fragment of PKA could also act as a transcription factor on CREB (Karin 
1992, Hunter 1995) (se below). cAMP is inactivated by enzymes with phospho­
diesterase (PDE) capacity (Hall 1989). The desensitization of the ß-adrenoceptors 
will be discussed in the prostacyclin section under Discussion. 
The phospholiphase C/D - protein kinase C system 
In addition, in this system the surface receptors are of the seven transmembrane-
spanning family, transmitting signals through the GTP-protein binding system. The 
effector enzymes, phospholipase C (PLC) and phospholipase D (PLD), are 
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associated with the cellular inner-membrane (Exton 1985, Liscovitch 1992, Roberts 
1996). 
PLC cleaves the membrane lipid phosphatidyl-inositol-biphosphate (PIP2), 
releasing inositol-trisphosphate (IP3) and diacylglycerol (DAG) into the cytosol (Lee 
1995). IP3 binds specifically to a receptor on the endoplasmatic reticulum, releasing 
Ca++to the cytosol. DAG could activate the multi-potent enzyme protein kinase C 
(PKC) or be further converted to arachidonic acid (AA) (Nishizuka 1995). 
PLD, being more unexplored, cleaves phosphatidyl-inositol or phosphatidyl­
choline to the second messenger phosphatic acid (PA). By an enzymatic reaction PA 
could be further converted to DAG, and this pathway probably represents the long-
lasting DAG phase after receptor stimulation (Exton 1990, Garcia 1992, Sozzani 
1992). 
The mitogen-activated protein (MAP) kinase system 
The amino acids, tyrosine, serine and theonine, could exist in two forms; phos-
phorylated, catalysed by kinases, or dephosphorylated, catalysed by phosphatases. 
Many proteins with these amino acids in their sequence could change conformation 
when phosphorylated. This three-dimensional shift could be accompanied by the 
unmasking of active enzyme sites. This newly-activated enzyme, if a kinase, could 
activate another pro-kinase and create a cascade reaction. To balance the system, 
phosphatases inactivate the kinases by dephosphorylering. 
The MAP kinase cascade or "extracellular signal-regulated kinases" (ERK) is so 
called for historical reasons, as the MAP kinase was the first enzyme in the cascade 
to be discovered. Surface receptors for several growth factors, cytokines and 
adhesion molecules, have intracellular regions that directly or indirectly could 
express kinase activity (Cobb 1991, Seger 1995, Hunter 1995). In a complex net of 
interactions, the activated receptor could interact with cell membrane, cytoskeleton 
or focal adhesion proteins through intermediating proteins (Grt>2, SOS, Shr, src-
family). The signal is transducted to the "small GTP-binding protein", Ras, a common 
converging point in the cascade. In a subsequent series of reactions, Ras activates 
the kinase Raf-1, activating the kinase MEK, activating MAP kinase. MAP kinase is a 
multipotent enzyme phosphorylating transcription factors, cell-cycle regulators, cyto-
skeletal proteins and phospholipid A2. Several points of interaction exist between the 
MAP kinase cascade and GTP-protein-coupled receptors (Lin 1993, v Corven 1993, 
Johnson 1994, v Biesen 1995, Erpel 1995, Post 1996, Bokoch 1996). Raf-1 is a 
kinase regulated by cAMP/PKA (Johnson 1994, Post 1996), and PKC (Kolch 1993, 
Nishizuka 1995). 
General intracellular signal systems: 
Ca4* system 
Ca*4-, an important co-factor, acts both extra and intracellular^. Inside the cell, 
Ca-"- is a fast and potent second messenger for many enzyme reactions, PLA2, nitric 
oxide synthases (NOS) and myosin light chain kinase. The free cytosolic Ca++ 
concentration is normally very low. Ca^ is stored by active ion-pumps into the endo­
plasmatic reticulum (ER) or excreted extracellularly. Phospholipase C -stimulated IP3 
could activate a receptor on the ER (Exton 1985, Adams 1989, Jacob 1990, 
Clapham 1995). The activated ER-receptor releases storaged Ca++ into the cytosol. 
The liberated Ca++ has been demonstrated to increase further Ca++ release, creating 
a fast wave of increased cytosolic Ca4^ concentration which sweeps over the cell. 
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This rapid Ca+^-flux is referred to the "initial high peak". The peak is followed by a 
lower but sustained "plateau phase", important both for enzyme activation and also 
for the refilling of intracellular Ca++ storage. This phase represents extracellular Ca++ 
influx through several differently regulated transmembrane channels. The influx 
depends both on the receptor-controlled probability of channel opening and the 
driving ion force created by the membrane potential (Adams 1989, Jacob 1990, 
Bezprozvanny 1991, Miyazaki 1995), Hence factors controlling transmembrane ion 
flux (K+, Na+, Mg++, H+) that could change the membrane potential (Sigel 1991, 
Graier 1993) or pH (Sweatt 1986, Madshus 1988, Kitazono 1989) have implications 
for the cytosolic Ca++concentration. Phosphorylating kinases could interfere with 
intracellular Ca++ by regulating transmembrane influx and refilling receptor-emptied 
ER storage (Fleming 1995). To sum up, Ca++ is an important intracellular activator. 
The cytosolic Ca++ concentration is the integrated sum of several cellular control 
mechanisms. 
Transcription Factors 
Transcription factors (TF's) are specialised molecules which transduct signals to 
the gene-promotor regions (Karin 1992, Hunter 1992, Hill 1995, Jans 1995). Some 
TF's are primarily located in the cytosol and transported to the nucleus when 
activated, whereas others are strictly intranuclear. TF's have different sequences for 
transporting the molecule into the nucleus for binding a specific part of the DNA and 
for activating DNA. Phosphorylation or de-phosphorylation of these separated 
sequences has been demonstrated to be used by different TF's to up- or down-
regulate gene activity. These regulatory mechanisms could explain why, for example, 
MAP kinase could induce a diverging effect with different TF's. Another principal 
influencing gene-promoter has been described for some hormones and growth 
factors where the entire agonist could be internalized and transported to the nucleus, 
where it could bind the gene (Jans 1995). 
The CRE (cAMP Response Element) sequence on DNA could be activated by 
phosphorylated CREB (CRE Binding protein) in complex with a member of the ATF 
family (ATF= Activating Transcription Factor). When cAMP activates cytosolic PKA, 
the C-terminal part of PKA will be released and transported into the nucleus. By 
phosphorylating CREB, the catalytic C-terminal initiates conformation changes and 
activation of the CRE sequence. Simultaneously, the C-terminal activates CREB-
inactivating phosphatases, shutting off the signal (Karin 1992, Wang 1992, Hunter 
1992, 1995, Hill 1995). 
The TPA responsive element (TRE) sequence of the DNA could bind transduction 
factors in the AP-1 (Activator Protein-1) family, which are different dimers of jun and 
fos. These TF's could be activated or deactivated in a complex net of interactions by 
PKC or kinases in the MAP cascade. The total activation is a function both of 
increased transcription of jun/fos (early response genes) and a modulated activation 
of latent jun. (Karin 1992, Wang 1992). 
Other kinases such as MAP/ERK42/45 and Rsk90 could also be translocated into 
the nucleus, phosphorylating intranuclear transcription factors (Johnson 1994). 
Nuclear Factor kappa Beta (NFKB) represents a type of TF that when bound to an 
inhibiting protein (IKB) is primarily located to the cytosol. Different "inflammatory" 
signals such as cytokines (IL-1, TNFA), endotoxin or PKC, could degrade the 
inhibitor (IKB), releasing NFKB. The "free" NFKB will then migrate into the nucleus, 
where it could influence several different genes and induce the cellular "inflam-
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matory" response. The degradation of IKB could be inhibited by serine protease 
inhibitors (Hill 1995, Thanos 1995). Hypothetical^, as PAI-2 induction is known to 
inhibit the inflammatory effect of TNFA (Dear 1995), NFKB / IKB might be one of the 
targets for intracellular PAI-2. 
Intracellular effector systems 
Finally, the modulated intracellular signal reaches effector systems. The product of 
these systems could be cell-surface-bound or secreted substances or a cytoskeleton 
rearrangement with or without a permeability shift. The effector system could react 
fast when the signal influence the activity of an already synthetized product, e.g. an 
enzyme. On the other hand, when the final product depends on a new protein syn­
thesis, the effector system has to have a lag-phase of transcription and translation. 
As this thesis focuses on the rapidly produced lipid metabolite prostacyclin and on 
the lag-phase synthetizsed glycoproteins t-PA and PAI-1, the synthesis pathways of 
this substances will be discussed / presented. 
The fast enzyme system, Arachidonic acid - Prostacyclin 
Arachidonic acid (AA) is created from membrane bound lipids, especially phos-
phatedyl-choline, cleaved by the enzyme, phospholipid A2 (PLA2). To a minor 
degree, intracellular DAG could also act as a source for AA. Free AA is rapidly 
converted to some of several different eicosanoids, (prostaglandins, leukotrienes, 
lipoxins). The synthesis pathway depends on the actual cellular access of enzymes. 
In endothelial cells, AA is converted by cyclooxygenase (COX) to the prostaglandin 
precursor, PGH2 (Dusting 1990, Liscovitch 1992, Gerritsen 1996, Roberts 1996). 
[Membrane phospholipids] 
(Fhospholipide A2 jPLÄg))—^ iDiacylglycerolTDÂG)! 
[Arachidonic AadlAÄ)] 
i 
FGG2I ( Lipoxygenases 
Thromboxane 
—(Cycioooxygenases (COX)) 
12/15 HPETE 
Leukotrienes 
"Prostacyclin synthetase) 
Prostacyclin^(PGI2) 
6-keto PGFia 
PGF2« pGE2 PGD2 
Fig 4. Metabolic pathways of eicosanoid biosynthesis. 
The enzyme COX is made up of two parts; a peroxidase and a cyclooxygenase. A 
intermediator in the synthesis (PGG2) irreversibly inactivates COX and a new protein 
synthesis is needed to recover COX activity. There are different types of COX. 
COX-1 is responsible for constitutive prostacyclin production and COX-2 for cytokin-
induced production (Shimizu 1994, Gerritsen 1996). 
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In endothelium, PGH2 is preferably converted to prostacyclin (PGI2) by PGI2-
synthetase, although a small amount of prostaglandin E2 (PGE2) and a trace amount 
of thromboxane A2 are also produced. 
The rate-limiting step (in the production of PGI2) is the activity of the enzyme 
PLA2. An important regulation of PLA2 is mediated by Ca++, bringing cytosolic PLA2 
in contact with the membrane substrates. The activity of PLA2 could also be 
regulated by receptor-induced GTP-binding proteins, MAP-kinases (Lin 1993, 
Johnson 1994, Seger 1995) and PKC (Nishizuka 1995). 
The slow gene-transcription system, t-PA and PAI-1 
t-PA and PAI-1 molecules could be secreted from the cell as a result of a series of 
cellular activities: activation of the promotor, transcription of DNA, translation to form 
the protein core, glycosylation in Golgi and, finally, excretion of the glycoprotein. As 
discussed earlier, several extracellular stimuli could induce t-PA and/or PAI-1 
production from endothelial cells. Briefly, inflammatory mediators, growth factors, 
adhesion substances and sheer stress use the MAP- kinase systems, whereas PLC 
activating substances use the PKC system. However, the signal transduction net­
work is complicated and has not been fully explored (Loskutoff 1989, Kooistra 1994, 
Chandler 1996). Regulation of the synthesis occurs mainly pre-transcriptionally. 
Post-transcriptional modulation regulating mRNA stability, Golgi sorting and 
phosphorylation is probably not that important in t-PA and PAI-1 production, as it is, 
for example, in u-PA synthesis (Loskutoff 1991, Gualandris 1995). 
The promotor area is the starting and control point of a gene. Several enhancer 
and repressor elements with affinity to specific transduction factors could be located 
in this DNA sequence. Every gene has a unique set of responding elements to 
control the transcription of mRNA for the coded protein (Medcalf 1990, Loskutoff 
1991, Ohlsson 1992). DNA regions and the function of several transcription factors, 
hormones and kinases have been described, by constructing and examining short 
sequences of the promotor. The results of these "split" experiments have sometimes 
been difficult to extrapolate to the in vivo situation, probably because of the 
occurrence of "transcription complex". Different TF's could "aggregate" into large 
"transcription complexes" creating a specific three-dimensional conformation thai 
could fit into and fold the DNA chain. This arrangement will permit the complex to 
simultaneously influence several separate regions on the promotor (Collins 1995, 
Edmondson 1996). 
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AIMS OF THE STUDY 
The general aim of the present investigation was to clarify the regulation of anti-
thrombogenetic factors in endothelial cells and particularly in relation to: 
the influence of adrenergic control in endothelial prostacyclin production, 
the regulation of tissue plasminogen activator (t-PA) and plasminogen activator 
inhibitor type-1 (PAI-1) production in endothelial cells, 
the differences in regulation of tissue plasminogen activator (t-PA) and 
plasminogen activator inhibitor type-1 (PAI-1) production in endothelial cells 
of different origin. 
To achieve this, the following experiments were performed: 
a. explorative studies, using agonists and antagonists representing different 
signal transduction pathways, 
b. cross-talking studies, examining the effect of adenylate cyclase and protein 
kinase C inhibition on endotoxin, phorbolester and thrombin-induced 
production, 
c. thrombin signal transduction studies, exploring GTP-binding protein and 
tyrosine kinase, 
d. comparative experiments on cultured human endothelial cells from umbilical 
veins and adult saphenous veins. 
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MATERIALS and METHODS 
Drugs 
The following substances and concentrations have been used in the experiments. Unless 
specified otherwise, all the substances were from Sigma Chemicals, Sweden. 
Forskolin, 1uM - 500uM, 
a direct adenylate cyclase activator, increasing the intracellular level of cAMP (Keen 
1992, Iyengar 1993). Stock solutions had to be dissolved in DMSO, the maximal final 
concentration 0,04% being atoxic. 
Isoprenalin (= isoproterenol),10"9 -10~5 M, 
a ßi - and ß2-adrenoceptor agonist. 
Ephedrine, 10"8 - 10"4 M, 
a ß- and a-adrenoceptor agonist. 
Isobutylmetylxantin (IBMX), 10"3M, 
a general phosphodiesterase (PDE) inhibitor, preventing cAMP degradation (Fredholm 
1980, Hall 1989). 
Propranolol, 10 5 M, 
a ß-|- and ß2-adrenoceptor antagonist. Propranolol has no intrinsic sympathetic activity 
(ISA) but has membrane-stabilising capacity. 
Metoprolol ,10"5 M, (Astra Hässle, Sweden) 
a semi-selective ßi-adrenoceptor antagonist with a dose-dependent ß2-receptor agonism. 
Metoprolol has no ISA and low membrane-stabilising capacity. Metoprolol isomers: S-
metoprolol with high and R-metoprolol with low ß-j-adrenoceptor antagonist effect, at the 
selected concentration (Harron 1981, Sandberg 1988, Wahlund 1990). 
Na-nitroprusside (NP), 10"9 - 10~5 M, 
a nitric oxide (NO) donator which stimulates the intracellular enzyme guanylate cyclase to 
produce cGMP. NP is unstable in bright light and the cell dishes had to be protected 
during the experiments (Harrison 1993). 
Endothelin-1 (ET-1), 10"12 -10~8 M (Peptide Institute INC, Japan), 
a polypeptide with an endothelial ETbi surface-receptor, linked to membrane G-proteins, 
PLC and Ca++channels (Masaki 1991, Eguchi 1993). 
Endotoxin (lipopolysaccharide LPS), 10~3- 10ug/ml, 
from E. Coli serotype 0111:84. Unknown transduction inducing intracellular 
phosphorylation. In vivo, probably most of the effect secondary to cytokine induction 
(Morrisson 1993, Müller 1993, Redl 1993). 
Phorbol 12-myristate 13-acetate (PMA), 1ng/ml-10ug/ml (=1,62nM - 16,2uM), producing a 
protracted activation of proteinkinase C (PKC) (Nishizuka 1995). 
H7 (1-(5-isoquinolinylsulfonyl)-2-metyl-piperazine), 5uM - 100uM, 
a dose-dependent, semi-selective PKC inhibitor at high concentration H7 can also inhibit 
cAMP (PKA) and cGMP-dependent protein kinase (Hidaka 1987). Stock solutions had to 
be dissolved in DMSO, with a maximal final concentration 0,01%, which is atoxic. 
a-Thrombin, 10"3 - 10U/ml, 
active thrombin from human plasma, without plasmin or plasminogen contents. 
Pertussis toxin, 100ng/ml, 
from Bordetella pertussis, by catalysing transfer of the ADP-ribose moiety of NAD to the 
a-subunit of the Gaj-protein inhibits the Gaj-protein in intact cells (Garcia 1991, Kaslow 
1992), 
Genistein, 2.5,10, 40ug/ml, 
a competitive ATP inhibitor, rather specific for tyrosine kinase, which blocks the 
transduction of signals in the MAP-kinase cascade, the IC50 being about 15 times lower 
for MAP-kinase than for protein kinase A or C (Akiyama 1991). IC50 for genistein 
decreased significantly with a low serum concentration (Hawker 1994), as used in the 
present study. 
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Stock solutions had to be dissolved in DMSO, with a maximal final concentration 0,065%, 
which is atoxic. 
Sodium ortho-Vanadate, 30, 100uM, 
an inhibitor of tyrosine-phosphatases (Gordon 1991). Stock solutions had to be warmed 
and alkalized; fina! test solutions had normal pH. 
Bovine serum albumin (BSA), 0.1% in cellular medium, 
to block unspecific binding sites in cell culture dishes. Endotoxin less than 0.1 ng/mg. 
Dimethyl Sulfoxide (DMSO), 
a detergent for hydrophobic substances. The final concentrations of DMSO never reached 
toxic levels (Levin 1989 ) and had no effect on t-PA or PAI-1 production (Data not 
presented). 
See the following section for the content of the cell-culture medium. 
Cell culture 
Endothelial cells were harvested in accordance with Jaffe (Jaffe 1973a) by incubating 
human umbilical cords or adult human great saphenous veins with a 0.1% collagenase, 
Worthington type 1 solution (Sigma Chemicals, Sweden), at 37°C. The vessels were gently 
manipulated, and after 12 minutes the cell and enzyme solutions were flushed with serum 
containing growth medium (see below). The cell suspensions were washed twice and 
seeded on tissue culture dishes. 
In paper I, primary cultures (passage 0) were used in the experiments and the cells were 
seeded directly on 1.9 cm2 tissue culture dishes (Corning, NY, US) precoated with human 
fibronectin 10ug/cm2 (Collaborative Research, US). In paper II - IV, primary cultures were 
seeded on 25 cm2 or 75 cm2 tissue culture dishes (Corning, NY, US) precoated with bovine 
gelatine 0.2% in cell culture medium (Sigma Chemicals, Sweden). 
In all the experiments the cells were grown in M199 medium with Earl's salt and 2.2 g/l 
sodium bicarbonate, supplemented with L-glutamine 0.234 mg/ml, penicillin 40 U/ml and 
streptomycin 40 ug/ml (all from Gibco, Sweden), heparin 100 ug/ml (Lövens, Sweden), 
ECGF 150 ug/ml prepared in accordance with Maciag (Maciag 1979) and 20% fetal calf 
serum (Kebo, Sweden). The cells were cultured at 37°C with 5% CO2 supplementation. The 
endothelial origin of the cells in culture was confirmed both by their typical morphological 
cobblestone appearance and by positive factor VIII immunofluorescence reaction (Jaffe 
1973b). For immuno-histochemistry, we used rabbit anti-human von Willebrand factor IgG 
and swine anti-rabbit FITC IgG (Dakopatts, Denmark). 
In paper II - IV, the cells were subcultured by adding a solution of trypsin 0.05% and 
EDTA 0.02% (Gibco, Sweden). The cell solutions were washed twice with serum containing 
growth medium, and then seeded on 1.9 cm2 tissue culture dishes (Corning, NY, US) 
precoated with bovine gelatine. In the experiments, quiescent endothelial cell cultures in 
passage 1 were used two days after reaching confluence 
Biochemical Analysis 
Prostacyclin 
6-keto-PGFia, the stable metabolite of PGI2 was analysed from the conditioned cell 
medium. A rabbit anti-6-keto-PGFia antibody was used in a |125.RIA technique (Du Pont, 
NEN). The cross-reactivity has been reported to be below 0.8% (=PGE-| ) for other eicosan-
oids. The range of the assay was 1 - 200pg/ml and dilutions of the samples were reported 
not to influence the measurement The coefficients of variation (CV) were described to be 
concentration-dependent, intra-assay (1.4%-5.2%) and inter-assay (6.8-12.4%). 
t-PA and PAI-1 
Commercially available enzyme-linked immunosorbent assays (ELISA) with polyclonal 
anti-human antibodies were used to determine the t-PA and PAI-1 antigen concentrations in 
the conditioned medium (TintElize t-PA and TintElize PAI-1, Biopool, Sweden). 
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The t-PA and PAI-1 antibody has been reported as detecting the different protein forms 
(single- or two-chain), active or latent, and the t-PA/PAI-1 complex with equal sensitivity. No 
cross-reactions with other cellular or cell medium substances have been detected. Down to 
an absorption of 0.050, the ranges of the assays were for t-PA 0.5 - 30ng/ml and for PAI-1 
0.5 - 40ng/ml. Dilutions of the samples did not influence the measurement. 
According to the manufacturer, the intra-assay coefficients of variation (CV) were 8% for t-
PA and 10% for inter-assay. For PAI-1, corresponding values were 5% and 11% 
respectively. 
Statistical Methods 
Changes were expressed as percentages of the basal release within the same 
experiment. 
In paper I, data were calculated with a two-way analysis of variance of logarithm values 
followed by multiple comparisons and are presented as ratios and 95% confidence intervals. 
In paper ll-IV, mean values are presented along with the 95% confidence intervals. Mean 
values exceeding the 95% confidence intervals in comparative groups were considered to be 
statistically significant. Differences were also tested for significance using the Wilcoxon rank 
sum test. p<0.05 was considered statistically significant. Significance testing, using either the 
95% confidence intervals or Wilcoxon rank sum test, gave identical results. 
Experimental design 
Prostacyclin 
In each experiment, primary cell cultures, originating from a single umbilical cord were 
used, seeded on multiple culture dishes. The cell dishes were handled gently throughout the 
experiment and placed in a CO2 incubator during incubation. 
The experiments were started by preincubating the cells for 15 minutes with blocking 
drugs (IBMX, metoprolol or propranolol) or pure medium M199, in accordance with the 
experimental design. After the preincubating period, the medium was replaced and the cell 
dishes exposed to 2 ml of new test solutions. The following combinations were added: a) 
pure medium M199, b) IBMX, c) IBMX + isoprenalin, d) IBMX + metoprolol, e) IBMX + 
propranolol, f) IBMX + isoprenalin + metoprolol, g) IBMX + isoprenalin + propranolol. The 
compositions were identical during the preincubation period, with the exception of isoprenalin, 
which was added only during the second incubation. All the test substances were dissolved in 
medium 199. This later incubation period lasted for 60 minutes. During the experimental 
period, the cell dishes were incubated at 37°C with 5% CO2. 
Samples of 0.2 ml were carefully collected from the conditioned medium. The samples 
were immediately mixed with an RIA-buffer containing 10ug/ml of indometacin before being 
frozen and stored at -70 °C until analysed. 
t-PA / PAI-1 
In each single experiment, cells derived from only one umbilical or saphenous vein were 
used. The cells, in passage 1, were plated on multiple cell-culture dishes and tested. Before 
the experiment, the culture dishes with endothelial cells were carefully washed twice with 
PBS-buffer. 
In paper IV, inhibitors were added during a separate preincubation period of 4 hours for 
pertussis toxin and 1 hour for genistein or vanadate. The experiments were started by 
adding 2ml of the different test solutions to the culture dishes. The substances and 
concentrations were in accordance with the experimental design of the study. All the test 
substances were dissolved in a cell-growth medium without fetal calf serum or ECGF but 
supplemented with 0.1% bovine serum albumin (endotoxin less than 0.1 ng/mg). During the 
experimental period, the cell dishes were incubated at 37°C with 5% CO2. 
Samples were collected from the conditioned medium after 16 hours, and in paper II also 
after 24 hours' incubation. The samples were immediately frozen, and stored at -70°C until 
analysed. 
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RESULTS 
Prostacyclin (PGI2) production 
Basal production 
Absolute basal release after 60 minutes of incubation ranged from 386 to 1554 
pg/105 cells. 
Stimulated prostacyclin production 
In the following, data is expressed as percentages of basal release (indexed to 
100%) in the same experiment, mean and 95% confidence interval of logaritmated 
values, n=numbers of cell dishes in the experiment. 
After 60 minutes of incubation, the PGI2 production was: IBMX (10"3 M) (109%, 
96-123%, n=5) which was almost identically to "basal" cells. Isoprenalin (10"6 M) 
(155%, 104-233%, n=5) significantly increased PGI2 production. Metoprolol (10-5 M) 
or propranolol (10"5 M) had no significant influence on PGI2, producing 143%, 96-
215%, n=5 and 160%, 53-266%, n=4 respectively. When isoprenalin (10"6 M) and 
metoprolol (10"5 M) were co-incubated, the PGI2 production increased even further 
to 299%, 199-448%, n=5. A combination of isoprenalin (10"6 M) and propranolol (10" 
5 M) also increased PGI2 production, 267%, 159-374%, n=4. (Fig 5.) 
Metoprolol Propranolol Isoprenalin Metoprolol Propranolol 
+lsoprenalin +lsoprenafin 
Fig 5. Samples from the conditioned medium of quiescent confluent cell cultures 
were collected after 60 minutes' incubation with IBMX 10"3 M, metoprolol 10~5 M, 
propranolol 10~5 M, isoprenalin 10"6 M and analysed for the stable PGI2 metabolite, 6-
keto-PGFia_ The results of the control dishes were set to 100%. Values are ratios 
related to control with 95% confidence intervals of logaritmated values, five separate 
experiments using different umbilical cords. 
To further explore whether the ß-adrenoceptor blocking capacity was of importance, 
metoprolol isomers with high (S-) or low (R-) blocking effect were tested. 
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Combinations of isoprenalin (10~6 M) and either the R- or S- metoprolol isomer (10"5 
M) gave almost identical results. The PGI2 production after 60 minutes' incubation 
was 193%, 121-306%, n=6 for R-metoprolol + isoprenalin and 198%, 125-315%, 
n=6 for S-metoprolol + isoprenalin. (Fig 6.) 
400 
2 
c 
8 300 
O 
S-Metoprolol R-Meîoprolol 
+Isoprenalin +lsoprenalin 
Fig 6. The effect of different metoprolol isomers 10"5 M, with high (S-) or low (R-) 
ß-blocking effect, in combination with isoprenalin 10"6 M on the prostacyclin production. 
Samples from the conditioned medium of quiescent confluent cell cultures were 
collected after 60 minutes and analysed for the stable PGI2 metabolite, PGF-|a.The 
results of the control dishes were set to 100%. Values are ratios related to control with 
95% confidence intervals of six separate experiments using different umbilical cords. 
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Fig 7. Time-course curves for PGI2 production from human umbilical vein endo­
thelial cells (HUVEC). Samples from the conditioned medium were collected after 
certain periods of time and analysed for the stable PGI2 metabolite, 6-keto-PGFia. a) 
Cell dishes preincubated with metoprolol, 10"5 M. Isoprenalin, 10"6 M, added at zero 
time, b) Cell dishes incubated with isoprenalin alone, 10-6 M added at zero time, c) 
Control cell dishes exposed to cell medium only. The data were normalized to the 
results from control dishes at time 60 min =100%. Values are mean ± SD of 3-15 
experiments. 
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Time-course 
Time-course curves were constructed for the basal and stimulated PGI2 
production. After a short lag-phase of about 6 minutes, the concentrations started to 
increase rapidly. This phase was followed by a successively decreasing synthesis 
rate, with stable concentrations during the later part of the experiment. Values from 
samples drawn after 60 minutes represented the total PGI2 production. The time-
curves of the stimulated and the non-stimulated cells were different in shape. The 
stimulated cells demonstrated a prolonged phase of rapidly increasing 
concentrations. (Fig 7.) 
t-PA and PAI-1 production 
Basal production 
The production of t-PA and PAI-1 varied between different cell cultures. Basal 
antigen production, presented as the mean basal antigen values and 95% 
confidence interval; n=numbers of cell dishes in the experiment. 
In paper I I I ,  which examines human umbilical vein endothelial cells (HÜVEC) and 
human adult vein endothelial cells (HAVEC), the basal antigen production was: 
t-PA: 
HUVEC 3,1±0.5 ng/105 cells, n=61, 
HAVEC 2.210.6 ng/105 cells, n=24 and for 
PAI-1: 
HUVEC: 111+16 ng/105 cells, n=57, 
HAVEC: 65±11 ng/105 cells, n=24. 
In paper IV, which only examines HAVEC, the basal antigen production was: 
t-PA: 1,5±0.3 ng/105 cells and for 
PAI-1: 106±17 ng/105 ceils, n=24. 
Agonist-stimulated t-PA and PAI-1 production 
All the data are expressed as percentages of basal t-PA or PAI-1 production 
(indexed to 100%) in the same experiment, mean ±95% confidence interval; 
n=numbers of cell dishes in the experiment. 
Human umbilical vein endothelial cells (HUVEC) 
In paper I I ,  agonists for several different cell surface receptors and second 
messengers were used to explore the regulation of t-PA and PAI-1 production from 
human umbilical vein endothelial cells (HUVEC). Dose-response experiments were 
performed. Samples collected after 16 or 24 hours from the start of the experiment 
varied in a consistent way, which is why data from the 16-hour samples only are 
presented. Data are presented as peak or nadir values in Fig 8. For complete dose-
response data see table I and II in paper II. 
Forskolin (1uM - 500uM) induced a significant, dose-dependent decrease in PAI-1 
production, at 10QuM to 61 %±16, n=12 of basal values. t-PA production was 
unaffected, (97%±16, n=13). These results were in contrast to the receptor 
agonists isoprenalin (10~9 M -10"5 M) and ephedrine (10-8 M -10"4 M), which had 
no effect on either t-PA or PAI-1 production. 
Na-nitroprusside (10~9 M -10-5 M) induced an increased PAI-1 production, at 105 M 
to 141 %±38, n=6, just reaching the level of significance. t-PA production remained 
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essentially unchanged. 
Endothelin-1 (ET-1) (10-12 M - 10"8 M). The production of neither t-PA nor PAI-1 was 
significantly influenced by ET-1 at any concentration. 
Phorbol 12-myristate 13-acetate (PMA) (1 ng/ml - 1 ug/ml =1.62nM - 16.2uM). PMA, 
in a dose-dependent fashion, significantly increased both t-PA and PAI-1 
production. The mean PAI-1 production at 0.1 ug/ml was 163%±35, n=20 and the 
mean t-PA was 350%+70, n=20, above basal control cultures. 
Thrombin (10~3 U/ml - 10 U/ml). The production of t-PA and PAI-1 was increased 
significantly in response to thrombin at concentrations from 10'2 U/ml and up to 
166%-195% and 130%-136%, n=10-17, above basal respectively. 
Endotoxin (LPS) (10-3 ug/ml -10 ug/ml ). Significant increases were attained only for 
the highest LPS concentration (10ug/ml) with a mean t-PA of 130%±209, n=14 
and PAI-1 production of 136%±30, n=15, above control values. 
% of Basal 
400-
= t-PA 
= PAI-1 
300-
200-
100-
Forskolin Isoprenalin Ephedrine Nitroprusside PMA Thrombin ET-1 LPS 
Fig 8. Peak and nadir values for tissue plasminogen activator (t-PA) and 
plasminogen activatot inhibitor type-1 (PAI-1) antigen from human umbilical vein 
endothelial cells (HUVEC). Data are expessed as a percentage of basal production 
(100%), means ±95% confidence intervals. Concentrations: forskolin 100uM; 
isoprenalin 10"5 M; ephedrine 10 "4 M; Na-nitro-prusside 10~5 M; PMA (phorbol ester) 
0.1 ug/ml (=0.162uM); thrombinIO U/l; LPS (endotoxin) 10 ug/ml. Samples were 
collected after 16 hours' of incubation. 
Human adult vein endothelial cells (HAVEC) 
In paper III, and in dose-finding experiments in preparation for this paper, the 
production of t-PA and PAI-1 from human adult vein endothelial cells (HAVEC) was 
examined. The cells were exposed to different agonists which were selected in 
accordance with the results in paper II. Samples were collected and analysed after 
16 hours of exposure. 
Forskolin (100uM) significantly decreased the basal PAI-1 production (42%±17, n=9) 
without affecting the basal t-PA production (90118%, n=9). In experiments 
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presented in paper IV, a weak but significant reduction in t-PA production was 
demonstrated, (74%±10, n=6). 
Phorbol 12-Myrstate 13-acetate (PMA) (0.1ng/ml =1,62uM) significantly increased 
the production of t-PA (1494%±407, n=22) and PAI-1 (221%±55, n=22). 
Thrombin (10 U/ml) significantly increased the production of both t-PA (359%±70, 
n=9) and PAI-1 (231%±48, n=9). These results could be repeated in the 
experiments presented in paper IV. 
Endotoxin (LPS) (10 ug/ml ) had no significant effect on the t-PA (100%±20, n=16) or 
on PAI-1 production (107%±19, n=15) from HAVEC. 
Modulation of agonist-stimulated t-PA and PAI-1 production 
"Cross-talk" 
In paper III, the ability to modulate endothelial t-PA and PAI-1 production induced 
by thrombin, LPS or phorbolester, was examined. In the experiments, different 
combinations of the agonists and forskolin or the PKC-inhibitor H7 were performed 
and tested. The production of human umbilical (HUVEC) and human adult (HAVEC) 
endothelium was compared. 
Co-incubation with H7 
H7 (5uM - 100uM), a PKC inhibitor per se reduced PAI-1 production in HAVEC at 
100uM (68%±17, n=15), but not significantly in HUVEC (82%±21, n=15). No effect 
could be demonstrated on t-PA production; HAVEC (96%±35, n=12), HUVEC 
(111%±17, n=14). 
When exposed to PMA, HUVEC and HAVEC increased their t-PA and PAI-1 
production. This induction was significantly reduced by co-incubating with the PKC 
inhibitor H7. 
Thrombin stimulated both HUVEC and HAVEC to increase their t-PA and PAI-1 
production. This agonist induction was significantly reduced by co-incubating with 
H7. 
Endotoxin modestly increased the production of t-PA and PAI-1 from HUVEC. This 
effect could be inhibited by co-incubation with H7. LPS had no effect on adult cells. 
However, when combined with H7, their production of PAI-1 decreased below 
basal but their t-PA production was unchanged. 
Go-incubation with forskolin 
Forskolin, as a single drug, in these experiments significantly decreased PAI-1 
production from both HUVEC and HAVEC without any effect on t-PA production. 
In HAVEC, but not in HUVEC, forskolin acts synergistically with PMA or endotoxin, 
increasing t-PA production (by a factor of 1.9 and 1.6 respectively) (Fig 9,11). 
Thrombin-induced t-PA production is modulated differently by forskolin depending 
on the type of cell. In HUVEC, the production was increased even further (by a factor 
of 1.3) but in HAVEC it was decreased (by a factor of 1.6) when thrombin was co-
incubated with forskolin (Fig 10). 
Examination of PAI-1 production revealed that, forskolin significantly decreased 
the response in HAVEC to PMA (by a factor of 2.7), to LPS (to 1.5), to thrombin (to 
3.0). 
Even in HUVEC, PAI-1 production was significantly decreased by co-incubating 
PMA (1.5), or LPS (1.6) with forskolin. However, in HAVEC, thrombin-induced PAI-1 
production was unchanged when forskolin was added. 
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Fig 9 The production of (t-PA) 
antigen from human umbilical 
vein endothelial cells (HUVEC), 
and from human adult vein en­
dothelial cells (HAVEC), after 16 
hours' incubation with phorbol 
ester 0.1 ug/ml (=0.162uM) and 
forskolin 10OuM. Data are ex-
pessed as percentage of basal 
ptoclucfcn (100%), means ±95% 
confidence intervals. Numbers 
of experiments: HUVEC: PMA 
n=20, PMA + forskolin n=12; 
HAVEC: PMA n=22, PMA + 
forskolin n=9. 
* p< 0.05 vs. PMA. 
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Fig 10 The production of (t-PA) 
antigen from human umbilical 
vein endothelial cells (HUVEC), 
and from human adult vein en­
dothelial cells (HAVEC), after 16 
hours" incubation with thrombin 
10U/ml and forskolin 100uM. 
Data are expessed as a per­
centage of basal picdudbn 
(100%), means ±95% confi­
dence intervals. Numbers of 
experiments: HUVEC: thrombin 
n=20, thrombin+forskolin n=9; 
HAVEC: thrombin n=9, thrombin 
+ forskolin n=9. * p< 0.05 vs. 
thrombin. 
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Forskolin Forskolin 
Fig 11 The production of (t-PA) 
antigen from human umbilical 
vein endothelial cells (HUVEC), 
and from human adult vein en­
dothelial cells (HAVEC), after 16 
hours' incubation with endotoxin 
(LPS) 10ug/ml and forskolin 
100uM. Data are expessed as a 
percentage of basal pioducfcn 
(100%), means +95% confi­
dence intervals. Numbers of 
experiments: HUVEC: LPS 
n=14, LPS +forskolin n=9; 
HAVEC: LPS n=16, LPS + 
forskolin n=9. * p< 0.05 vs. 
LPS. 
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Thrombin signal transduction regulating t-PA and PAI-1 production 
In paper IV, thrombin signal transduction preceding t-PA and PAI-1 production in 
aduit endothelial cells, especially the role of G«i -protein and tyrosine kinase, was 
examined. In preparation for this paper, a phosphatase inhibitor (sodium ortho-
vanadate) was tested and comparative experiments were performed on human 
umbilical cells. 
Pertussis toxin 
In these first experiments, thrombin (10U/ml) significantly increased t-PA and 
PAI-1 production (234+42% and 211±42%, n=18 respectively). Pertussis toxin 
(100ng/ml), which inhibits Gai -protein, reduced basal PAI-1 (66%±8, n=18) but only 
moderately affected basal t-PA production (88%±10, n=18). Cells pretreated with 
pertussis toxin produced significantly less t-PA and PAI-1 when stimulated with 
thrombin, (142%+23, n=18 and 146%±19, n=18 respectively). Forskolin, (100uM) in 
this experiment, had a weak influence on basal t-PA production (74%±10, n=6) but a 
stronger effect on basal PAI-1 production (51 %±4, n=6) of non-stimulated value. 
Forskolin could significantly decrease thrombin-induced production of both t-PA and 
PAI-1 (91%±7 and 46%±8, n=6, respectively). When pertussis toxin was also added 
to the co-incubation between thrombin and forskolin, only a very limited additional 
inhibitory effect could be recorded. t-PA production decreased (75%±15, n=6) and 
PAI-1 was virtually unchanged (50%±5, n=6) (Fig 12). 
% of Basal 
300-r-i— 
Basal Pertussis toxin Thrombin Thrombin Forskolin Thrombin Thrombin 
Pertussis toxin Forskolin Forskolin 
Pertussis toxin 
Fig 12. The production of tissue plasminogen activator (t-PA) and plasminogen 
activator inhibitor type-1 (PAI-1) antigen from human adult vein endothelial cells 
(HAVEC), after 16 hours' incubation with thrombin 10U/ml, n=18; pertussis toxin (PTX) 
100ng/ml, n=18; forskolin 100uM, n=6, and combinations (thrombin + forskolin n=18 ; 
other combinations, n=6. Data are expressed as a percentage of basal production 
(100%), means ±95% confidence intervals. 
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Genistein, Sodium ortho-vanadate 
Genistein, a tyrosine kinase inhibitor, was tested in a separate set of experiments 
against thrombin. Preincubation with genistein significantly reduced thrombin 
induction of both t-PA and PAI-1 production. The effect was dose-dependent. In 
these experiments, genistein, 2.5ug/ml or 10ug/ml or 40ug/ml, reduced the thrombin-
stimulated t-PA production from 315%±89 to 128%±54, 98%±18 or 77%±14, n=6 
respectively. The thrombin-stimulated PAI-1 was decreased from 282%±96 to 
78%±35, 32%+9 or 29%±17, n=6 respectively. 
Sodium ortho-vanadate, a tyrosine phosphatase inhibitor per se (30uM), had no 
significant influence on either basal t-PA (140%±57) or PAI-1 (94%±31, n=6), 
production. When combined, vanadate 30uM or 100uM reduced thrombin-stimulated 
t-PA production in this experiment from 310%±45 to 204%±69 or 232%±53, n=6, and 
thrombin-stimulated PAI-1 from 248%±38 to 129%±39 or 123%+29, n=6. (Fig 13). 
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Fig 13. The production of tissue plasminogen activator (t-PA) and plasminogen 
activator inhibitor type-1 (PAI-1) antigen from human adult vein endothelial cells 
(HAVEC), after 16 hours' incubation with thrombin 10U/ml, genistein 2.5 - 40ug/ml, and 
combinations for 16 hours, n=6. Data are expressed as a percentage of basal production 
(100%), means ±95% confidence intervals. 
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DISCUSSION 
Discussion of methods 
A cell culture system allows comparisons to be made under defined and identical 
experimental conditions. Even if the use of culture systems has been almost routine 
in metabolic studies (Kooistra 1990), it is important to consider that the extrapolation 
of data to the in-vivo situation has to be carried out with great care. 
Methods in prostacyclin study 
Endothelial cells in culture, have been demonstrated to be a suitable model for 
functional pharmacological studies exploring prostacyclin production. When synth­
esized, prostacyclin is instantly released from the cell and no intracellular storage 
pools have been detected (Levin 1984, Jaffe 1987, Dusting 1990, Gerritsen 1996). 
Hence accumulation in the conditioned medium is likely to represent the total PGI2 
production. 
Prostacyclin (PGI2) has a short half-life and spontaneously converts to the in­
active metabolite 6-keto PGF1a (Moncada 1990, Dusting 1990). In vitro, antigen 
measurement of this metabolite is representative of PGI2. However, in-vivo plasma 
measurements of 6-keto PGF-|a are an unreliable method and the analysis of urine 
excretion of 6-dinor-keto- PGF1a has proved to be a better one (Greén 1986, 
Wennmalm 1990, 1992). The importance of having a specific antibody has been 
stressed (Patrono 1987). The antibody used in this experiment is rather selective 
and the method reliable in the actual concentrations. 
Cyclooxygenase being an irreversible desensitizating enzyme complex needs a 
lag-phase of protein synthesis to restore enzyme activity after inactivation (Duniec 
1990, Shimizu 1994, Gerritsen 1996). Consequently, the pre-experimental handling 
of the cells is crucial for the PGI2 production. In the present study, the cell cultures 
have been investigated, unperturburated at confluence. 
Cells cultures originating from different umbilical cords have been reported to 
have large quantitative but no qualitative differences in PGI2 production (Adler 1981, 
Levin 1984). To correct for these variations, all the data were related to the basal 
non-stimulated cultures in the same experiment. 
Concentration of ß-adrenoceptor blocker metoprolol and propranolol (10"5 M) were 
selected to give a high receptor binding rate. The peak plasma concentrations of 
metoprolol in vivo reaching 10"6 M (Harron 1981, Sandberg 1988). At a plasma-
correlated metoprolol concentration of 10"5 M, the ß-adrenoceptor blockade was 
maximal for S-isomers but only about 15% for R-isomers (Wahlund 1990). 
Methods in tPA PAI studies 
Endothelial cells in culture constitute a well-documented experimental model for 
studying tPA and PAI-1 production (Gerard 1989, Loskutoff 1989, Kooistra 1990, 
1994). For t-PA and PAI-1, correlations have been demonstrated between the 
following methods: immunohistology, in situ hybridization, tissue extraction analysis 
and protein secretion (Schleef 1990, Quax 1990, Simpson 1991, Sawdey 1991, 
Keeton 1993, vd Eijnden-Schrauwen 1995, Padrö 1990). The production of t-PA or 
PAI-1 from cultured cells could be estimated by measuring activity or antigen in the 
conditioned medium or by quantifying intracellular mRNA. Antigen and mRNA 
methods are time specific but comparable for the detection of total t-PA or PAI-1 
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production, (Declerch 1988, Sawdey 1991, Amman 1993), whereas activity methods 
measure the sum of activators and inhibitors (Eriksson 1988). As different antibodies 
are sensitive for specific epitopes or molecular conformations of t-PA and PAI-1, 
absolute values using different antibodies could not be compared (Perrie 1993). In 
the present studies, a polyclonal coating-antibody, recognising all forms of t-PA or 
PAI-1, was used. Measurements were performed at reliable antigen concentrations. 
The acute release of t-PA from cellular pools and of PAI-1 from extra-cellular 
matrix pools have been described. These pools were quite small and the release 
correlated to the slower cellular synthesis rate (Levin 1987, Knudsen 1988, Mimuro 
1989a, Schleef 1990, vd Eijnden-Schrauwen 1995). Hence the antigen accumulation 
in the medium during the experiment was likely to represent the total cellular t-PA 
and PAI-1 synthesis (Schleef 1990, Kooistra 1994, vd Eijnden-Schrauwen 1995). 
The synthesis of t-PA and PAI-1 from cultured endothelial cells could be 
influenced by several factors: phenotype, number of passages, state of confluence or 
culture medium content. Even under identical culture conditions, large quantitative 
variations have been observed between different cultures (v Hinsbergh 1987, Dichek 
1989). To reduce these problems in the present study, both cellular and cultivation 
conditions were kept identical in all the experiments. Absolute production data were 
related to basal, non-stimulated, control cultures in the same experiment. 
Serum, added to the culture medium, contains several different stimulating 
substances such as growth factors including TGFß (v Hinsbergh 1987, Cobb 1991, 
Moolenaar 1995). To minimize this non-specific effect, which interferes with the 
production of t-PA and PAI-1, the experiments were performed under serum-free 
conditions. The release of t-PA and PAI-1 to the conditioned medium, after a lag-
phase, progressed at a relatively constant rate. The duration of the incubation has to 
be adjusted for the sensitivity of the measuring methods, the pharmacology of the 
test substances and for practical reasons. A period of 16 hour' exposure to the test 
drugs was selected in the present study as the optimal experimental time. 
Prostacyclin production 
Prostacyclin, secreted from endothelial cells, could decrease platelets aggregation 
and adhesions but could also relax smooth muscle cells in the vessel wall (Moncada 
1990, Vane 1990, Busse 1993). 
Prostacyclin, Hypertension, Adrenergic tonus 
In a population with norma! blood pressure, a relationship has been demonstrated 
between high adrenergic tonus and an increased production of PGI2 (Wennmalm 
1990). On the other hand, various studies have demonstrated that individuals with 
hypertension have high adrenergic tonus (Tuck 1986, Åblad 1988) and paradoxically 
low PGI2 production (Fitzgerald 1987, Beckmann 1988, Frölich 1990, Minuz 1990). 
A hypothesis is that decreased prostacyclin production resulting from a patho­
physiological adaptation to high adrenergic tonus could be of etiologic importance in 
hypertension. The adrenergic modulation of endothelial prostacyclin production has 
attracted great interest (Adler 1981, Pettersson 1991), but is still not completely 
understood. We have tested the hypothesis that prostacyclin production is regulated 
by adrenergic mechanisms. 
Results in the present study 
In our pre-non-stimulated cell-culture model, the {^-adrenoceptor agonist 
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isoprenalin gave a small but significant increase in PGI2 production. This result 
corroborated other in-vivo studies (Schaffer 1982, Williams 1989, Wennmalm 1990) 
but diverged from certain in-vitro studies (Adler 1981, Jeremy 1985). However, Adler 
and Jeremy used pre-stimulated cell models, constructed to estimate the capacity of 
isoprenalin to modulate an ongoing PGI2 synthesis and not to initiate the synthesis. 
in the present study, a combination of isoprenalin and a ß-adrenoceptor 
antagonist, metoprolol or propranolol, increased the PGI2 production even further. 
This synergism has not previously been reported when cultured endothelial cells have 
been used. However, similar effects have been demonstrated jn other experimental 
systems, in vivo from humans (Beckmann 1988) and rabbits (Åblad 1988) and in vitro 
on guinea pig hearts (Löbel 1985) and rat aortas (Nishimiya 1990, Hirawa 1991). 
The possibility that PGI2 was increased by ß-adrenoceptor blockers alone could be 
contradicted, as in the present study, metoprolol or propranolol did not significantly 
affect the basal PGI2 production. This result agreed with other reports in vivo (Greén 
1986, Wennmalm 1992) and in vitro (Adler 1981, Nishimiya 1990, Hirawa 1991). 
To further explore the synergistic effect of isoprenalin and ß-adrenoceptor 
blockers, metoprolol isomers with either high or low receptor blocking activity were 
examined. Both isomers, when co-incubated with isoprenalin, were found to have an 
equally synergistic effect on PGI2 production. Consequently, the synergistic effect 
could be separated from the ß-adrenoceptor antagonistic effect of metoprolol. Effects 
not related to the ß-adrenoceptor blocking capacity have been reported earlier for 
different isomers of propranolol (Cambell 1981, Chobanian 1985, Callahan 1986). 
However, other studies have demonstrated effects caused only by the active isomer 
(Löbel 1985, Nishimiya 1990). 
Intracellular cAMP, induced by adrenoagonists, has been reported to have a short 
half-life due to phosphodiesterases (PDE) activity. To strengthen any cAMP effect in 
the experiment, we and others have inhibited PDE with isobutylmetylxantin (IBMX), a 
well-documented inhibitor of different PDE isomers (Adler 1981, Hall 1989, 
Manolopoulos 1995a). IBMX has also been demonstrated to have other effects, 
inhibiting adenosine receptors (Fredholm 1980) and, in high concentrations, even 
phospholipase C (PLC) (Matsuzawa 1980). Brotherton (Brotherton 1982) pointed out 
that IBMX could have an inhibitory effect on PGI2 production in experimental cell 
models when pre-PLC-stimulation was used. In our experimental cell model, no pre-
PLC-stimulation or adenosine agonists that could be inhibited by IBMX were used. 
Hence in the present study, IBMX per se had no effect on basal PGI2 production. 
Signai transduction - Hypothesis 
These experiments could not clarify the intracellular interactions behind the 
synergistic effect of isoprenalin and metoprolol or propranolol. However, from studies 
using other experimental cell systems which explored signal transduction, a working 
hypothesis could be formulated. The hypothesis will be discussed in the following 
section, structured according to the site of interaction: 1) with phosholipase A2 
(PLA2), the key enzyme in the cascade, 2) with the ß-adrenoceptor or 3) with other 
pharmacological side effects. 
- 3 4 -
1) Interaction with PLÂ2 
Recent reports have described two mechanisms responsible for PLA2 activation. 
a) Ca++ induces translocation of cytosolic PLA2 to the membrane creating direct 
contact with the phospholipid substrates. 
b) MAP kinase phosphorylation of PLA2 increases the activity of the enzyme 
(Lin 1993). 
a) Ca++ induced translocation of cytosolic PLA2 
There are, in principle, two ways to increase the intracellular Ca++ concentration: 
a rapid receptor-regulated release from intracellular storages and a slower trans­
membrane influx (see Introduction). 
The release from intracellular stores (ER) is dependent on receptor-mediated PLC/ 
IP3 activity and no ß-adrenergic regulation has been described. 
The transmembrane Ca++ influx could be regulated both by a controlled opening of 
the transmembrane ion-channels and by the electrical ion-force created by the 
membrane potential. In endothelial cells, which have no voltage-dependent channels 
(Adams 1989), the probability of a Ca++ ion-channel opening is regulated by 
receptors (Lückhoff 1992). Membrane hyperpolarization by K+ influx, increases Ca++ 
ion force and influx. In platelets and cardiac muscle cells, adrenoceptors connected 
to GTP-binding proteins could regulate K+ channels and the Na++/H+ pump (Sweatt 
1986, Barber 1989, Schubert 1989). In endothelium, K+ channels are regulated by 
cell receptors, GTP-binding proteins, cAMP, intracellular Ca++ and H+ concentrations 
(Adams 1989, Siege! 1991). Sheer stress could also open endothelial K+channels 
(Olesen 1988), and activate tyrosine kinases (Berk 1995) corresponding to the flow-
induced PGI2 production (Frangos 1985). Increased intracellular pH, created by the 
Na++/H+ antiport (Madshus 1988), could increase PLA2 activity, both in platelets 
(Sweatt 1986, Limbird 1988) and in endothelium (Kitazono 1989). 
The cytosolic Ca++ concentration could be decreased by active ion-pumps. cAMP 
/ PKA modulation of these pumps has been described for smooth muscle and cardiac 
muscle cells but not for endothelium (Braunwall 1982). 
From this section (1a), the following hypothesis may be formulated: 
Isoprenalin and/or metoprolol / propranolol could (via GTP-binding proteins) 
induce a shift in transmembrane K+, Ca++, H+- flux. These shifts could increase, 
directly or indirectly, intracellular Ca++or pH, stimulating PLA2 activity and PGI2 
production. 
b) MAP kinase phosphorylation of PLA2 
MAP kinase activity has proved to be a converging point for several signals 
induced by GTP-binding proteins, growth factors, cytokins, adhesion molecules and 
sheer stress (Johnson 1994, Seger 1995, Post 1996). Since MAP kinase could phos-
phorylate and activate PLA2 (Lin 1993). Tentatively, interference with preceding 
enzyme-steps in the MAP cascade could modulate the final PGI2 production. 
Both isoprenalin, through the ß-adrenoceptor (Barber 1989, Schubert 1989, 
Williams 1989, Yatani 1989, Williams 1995) and receptors linked to the PLC system 
(Burch 1990, Garcia 1992), has been reported to dissociate GTP-binding proteins 
that could activate PLA2. Ras, an oncogen preceding MAP-kinase, could be inhibited 
by cAMP/PKA (Johnson 1994). This might be the point of action for cAMP/PKA-
inhibited PLA2 reported in platelets (Schäfer 1984). However, endothelial data 
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according this effect diverge (Adier 1981, Brotherton 1982, Hong 1985). 
From this section (1b), the following hypothesis may be formulated: 
a) Isoprenalin could stimulate, directly or indirectly, the MAP-kinase cascade 
and further PLA2 by dissociating membrane GTP-binding proteins (Schubert 
1989, Garcia 1991, Clark 1993, Post 1996). 
b) The MAP kinase cascade could be inhibited at the Ras/raf-1 step by cAMP / 
PKA (Johnson 1994, Post 1996). Metoprolol/ propranolol could either reduce 
the cAMP/PKA inhibition or increase the MAP-kinase stimulation, creating a 
synergistic effect on PGI2 production. 
2) Interactions with the ß-adrenoceptor 
The ß-adrenoceptor could be rapidly and reversibly desensitizated by PKA. This 
inhibition could be further increased by ß-AR kinase, phosphorylating the receptor. 
After prolonged agonist exposure, the receptor degrades and has to be replaced by a 
new protein synthesis (Hausdorff 1990, Keen 1992). In perfused rabbit hearts, 
Williams (Williams 1989) found isoprenalin-induced prostacyclin production to be 
paradoxically decreased by cAMP/PKA. The results indicated a non-cAMP-trans-
ducted prostacyclin-increasing effect of Gas, as described for ion-channels (Barber 
1989, Schubert 1989, Yatani 1989, Williams 1995). Furthermore the effect of ß-AR 
kinase could be increased and the ß-adrenoceptor desensitized by PKC (Winsel 
1996). Even other pathways, phosphorylation ß-AR kinase, probably exist, but the 
regulation is still unknown. By rearranging membrane structures PLA2 activity could 
also decrease the receptor binding capacity (Cohen 1985, Williams 1995). 
3) Interactions with other pharmacological side effects 
By sensitizing PLA? for Ca++, calmodulin has been demonstrated to increase the 
activity of PLA2 in platelet, hepatic and gastric mucosal cells (Vanderhoek 1979, 
Matzusawa 1980, Olaisson 1990), although contradictory results have been 
published on endothelial cells (Adler 1981, Jaffe 1986). Propranolol in high doses 
has been reported to inhibit calmodulin, an effect not related to the ß-adrenoceptor 
(Volpi 1981). 
Propranolol in high doses has also been demonstrated to inhibit platelets PLA2, 
(Vanderhoek 1979, Cambell 1981, Callahan 1985), hepatic phospholipase C (PLC) 
(Matzusawa 1980), proteinkinase C (PKC) and the conversion of phosphatic acid 
(PA) into diacylglycerol (DAG) / arachidonic acid (Sozzani 1992). These effects were 
not related to the ß-adrenoceptor. On the other hand, Das (Das 1988), using human 
neutrophils, demonstrated increased inositol-phosphate production (PLC effect) 
when propranolol was added. 
Cyclooxygenase is irreversibly auto-desensitized when converting arachidonic 
acid to prostacyclin precursors (Shimizu 1994, Gerritsen 1996). This desensitization 
could be prevented by scavengers. Löbel (Löbel 1984) hypothesized that ß-adreno­
ceptor blockers could act as scavengers. 
From this section (3), which mainly reports inhibitory side-effects of propranolol, no 
hypothesis could be formulated to fit the stimulatory effect that was found in the 
present study. The results reported by Das and Löbel could have been of interest, 
but they have not been confirmed by others. 
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Summary 
In the present study, isoprenalin and ß-adrenoceptor antagonists such as 
metoprolol or propranolol synergistically increased prostacyclin production from 
endothelial cells. The effect could not be associated with the ß-adrenoceptor-blocking 
effect per se. The intracellular background for this synergism is not clear at present, 
although a working hypothesis could be formulated. 
The results corroborated previous clinical reports and may offer a hypothesis as to 
why only hypertensive individuals, characterised by high basal adrenergic tonus and 
paradoxically low PGi2 production, react with increased PGI2 production when 
undergoing ß-adrenoceptor-blocking therapy. 
Isoprenalin Ca++ 
|W| 
PGI2 
AA 
'aq 
Ca++ 
Adenylate cyclase PLC 
MAP 
PKC 
AMP *- cAMP. 
PKA 
Fig 14, Intracellular interactions behind the synergistic effect of isoprenalin and 
ß-adrenoceptor antagonists, on endothelial prostacyclin production. Summary of 
hypothesis. 
Î-PA and PÄI-1 production 
Agonist signals could be transducted through many different "cross talking" intra­
cellular pathways. To explore these interactions and to modulate endothelial t-PA 
and PAI-1 production, substances with well-known intracellular pathways were 
tested. Furthermore, endotoxin, a substance with high biological activity but un­
classified signal transduction, was selected. In a first series of experiments (paper 
II), the substances were added as single drugs and dose-response curves were 
performed. With the results in paper II as a basis, phorbolester, thrombin and endo­
toxin were selected to be co-incubated with forskolin or the PKC inhibitor, H7 (paper 
III). Thrombin, being a central biological substance with complex trans-duction> was 
further examined using inhibitors to GTP-binding proteins and MAP kinases (paper 
IV). The structure in the following section is based on a presentation of examined 
agonists, with or without co-incubation. Agonists using the same signal pathway 
have been presented together. 
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Endotoxin (LPS) Na-nitroprussid 
Ephedrine 
-V]—Q-
GaS-ßY Gai-ßY 
Thrombin 
? Endothelin-1 Isoprenalin 
NO 
Phorbolester 
(PMA) IW1 Forskolin 
\ PLC 
Ca++ 
DAG 
MAP Adenylate cyclase 
v 
Guanylate cyclase 
PKC cGMP 
AMP >- cAMP H7 
PKA 
Nucleus 
Protein synthesis 
i 
t-PA / PAI-1 
Fig 15. Agonist stimulated t-PA and PAI-1 production. Summary of explored pathways. 
Isoprenalin, with predominating ß- and ephedrine with combined a- and ß-
adrenoceptor activation. The ß-receptor is connected to the Gas -protein and the a-
receptor to the Gai -protein. The activity of the enzyme, adenylate cyclase, producing 
cAMP, could be increased by Gas or decreased by Gai respectively (Sibley 1985, 
Limbird 1988). In the present study (paper I!), using umbilical cells, neither 
isoprenalin nor ephedrine demonstrated any influence on t-PA or PAI-1 production. 
Forskolin binds to and directly activates adenylate cyclase, increasing the 
intracellular level of cAMP (Sibley 1985, Iyengar 1993, Manolopoulos 1995a). In the 
present study (papers II, III), both adult and umbilical cells exposed to forskolin 
significantly decreased PAI-1 production but had only minimal influence on t-PA 
production. These results were in line with other reports (Santell 1988, Francis 1989, 
Kooistra 1991, Slivka 1991). The divergence in cAMP-modulated production 
indicated separate regulatory pathways for t-PA and PAI-1. The incapacity of 
isoprenalin to influence PAI-1 could be explained by rapid adrenoceptor 
desensitization following agonist exposure. Forskolin with a direct enzyme activation 
engendered no desensitization (Sibley 1985, Hausdorff 1990). 
Na-nitroprusside (NP) has been demonstrated to generate nitric oxide (NO), 
stimulating guanylate cyclase to produce cGMP (Brotherton 1986, Harrison 1993). 
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In the present study (paper Ii) in which umbilical cells were used, NP increased 
PAI-1 production slightly, albeit significantly, but had no influence on t-PA production. 
However, the results could be disputed as the number of experiments was low and 
the effect not strictly dose-dependent. No NP effect could be detected on the rapid t-
PA release from rat and human cells respectively (Tranquille 1993, Jem 1994). 
Increased fibrinolysis has been reported in rabbit; following NP administration, the 
hypothesis being that this is due to an inhibitory effect on PAI-1 release from 
platelets (Lidbury 1990). In-vitro cGMP was described (data were not presented) as 
having no influence upon PAI-1 incorporation in matrix (Slivka 1991). In a recently 
published study, no influence on either t-PA or PAI-1 production could be 
demonstrated when umbilical cells incubated with NP and fetal calf serum were used 
(Pannocchia 1996). 
Endothelin-1 (ET-1) has been demonstrated to be a potent vasoactive poly­
peptide in the endothelin family. ET-1 could activate a set of different endotheiin 
receptors, inducing biological effects on several types of cell. As they have non­
selective ETßi receptors, endothelial cells could, in a autocoid manner, both produce 
and respond to ET-1. The cell receptors belong to the seven transmembrane-
spanning, and GTP-binding-protein family. In endothelium, the receptor has been 
reported to be connected to G«q and God-protein. Agonist-binding increased 
cytosolic Ca++ concentration by activation of phospholipase C and by opening cell 
membrane channels. In endothelium, ET-1 releases NO and PGI2 (Vane 1990, 
Masaki 1991). ET-1 could also decrease cAMP (Eguchi 1993). 
In the present study (paper II) on umbilical cells, incubation to ET-1 had no effect 
on their t-PA or PAI-1 production. Results from other studies exploring the effect of 
endothelin on fibrinolysis diverge. In a study using rabbits, administration of ET-3 
increased fibrinolysis (Kornbut 1989). In an in-vitro study, an umbilical cell-line, when 
exposed to ET-1, decreased t-PA production 25%, but had no effect upon PAI-1 
production (Yamamoto 1992). 
Protein kinase C (PKC) has revealed itself to be a potent intracellular phos-
phorylating enzyme, central to signal transduction. PKC has been demonstrated to 
modulate receptors, GTP-binding proteins, membrane lipases, ion-channels, intra­
cellular enzymes and transcription of both pro-oncogenes and secreted proteins. 
The multi-substrate capacity of PKC could result in a broad spectrum of diverging 
intracellular signals. The final cellular response upon PKC activation is determined 
both by the intracellular localisation and by other modulating transducted signals 
(Kooistra 1991, Kolch 1993, Lin 1993, Nishizuka 1995, Thanos 1995, Winstell 1996). 
Diacylglycerol (DAG), a metabolite with a short half-life produced by membrane 
phospholipase C or D is the natural activator of PKC. The effect of DAG could be 
imitated by exogenously-added phorbolester (PMA), producing long-lasting PKC 
activation. When activated, cytosolic PKC translocates and binds to the cell 
membrane. PKC exists in the form of several different isomers, which have different 
characteristics (Nishizuka 1995). In the present study, PMA increased t-PA and PAI-
1 production, both in umbilical and adult endothelial cells. Adult cells are 
proportionally even more active in respect of t-PA production. Several studies have 
presented similar results (Santell 1988, Levin 1989, Francis 1989, Slivka 1991, 
Kooistra 1991). 
H7, an isoquinoline sulfonamide, has been presented as a dose-dependent semi-
selective PKC inhibitor. A high concentration of H7 could also inhibit cAMP (PKA) and 
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cGMP-dependent protein kinase (Hidaka 1987), In our experimental model, both H7 
and forskolin decreased PAI-1 production, but only forskolin increases PKA activity. It 
thus seemed unlikely that H7 had any significant PKA-inhibiting effect. As cGMP has 
been demonstrated to have a minimal effect on fibrinolysis (paper II), a potential 
inhibiting effect by H7 must be insignificant. 
In the present study, adult endothelial cells exposed to H7 decreased PAI-1 
production significantly, whereas production in umbilical cells was insignificantly 
reduced. However, t-PA production was not influenced in any type of cell (paper III). 
In control experiments, both adult and umbilical cells reduced PMA-induced t-PA and 
PAI-1 production when co-incubated with the PKC inhibitor H7. The reduction was 
approximately 50% at a H7 concentration of 10QuM (paper III). Similar results have 
been reported earlier (Levin 1989, Grulich-Henn 1990, Shi 1996). 
In paper III, we examined the production of t-PA and PAI-1 from cells exposed to a 
combination of PMA and forskolin. In both types of cell, PAI-1 production was found 
to be decreased by co-incubation with forskolin compared with cells exposed to PMA 
alone. The reduction was proportional to the effect of forskolin per se, contradicting 
synergism. Production of t-PA induced by PMA was further increased by co-
incubation with forskolin in adult, but not in umbilical, cells. 
Several reports demonstrated that forskolin, or other cAMP-increasing 
substances, could decrease PMA-induced PAI-1 production (Santell 1988, Slivka 
1991, Kooistra 1991). On the other hand, when umbilical cells were used, the lack of 
synergism in t-PA production was at variance with some of these studies (Santell 
1988, Kooistra 1991). However, the experimental models were not identical with 
respect to serum and growth factor supplements. 
Construction of the t-PA gene with several dynamic, positive and negative 
modulatory feedback mechanisms might explain both the synergistic effect and the 
diverging results in different reports (Medcalf 1990, Ohlsson 1992, Karin 1992). The 
human t-PA promotor contains a TATA box, but the most important points of 
regulation have been demonstrated to be two GC-boxes further downstream. The 
first GC box harbours a "CRE-like" sequence with one nucleotide shift inside and 
several changes outside the CRE-sequence, giving a low affinity for CREB. This 
sequence could bind the PKC-induced jun/fos dimers from the AP-1 family instead 
(Ohlsson 1992). The other GC-box harbours an AP-2 response element that could 
be activated both by CREB/ ATF and jun/fos dimers. The "CRE-like" and AP-2 -
responding elements could act separately or synergistically when stimulated with 
PMA-activated PKC /jun/fos and forskolin-induced cAMP/CREB (Rickles 1989, 
Medcalf 1990). Jun/fos and CREB/ATF are simultaneously both activated and 
inhibited by transcription factors whereby TF's creates a unique and dynamic 
regulatory balance (Karin 1992). 
The human PAI-1 promotor regulates through a specific set of protein - nucleic 
acid interactions, but with a higher degree of conservation between species than the 
t-PA promotor (Loskutoff 1991). In addition to jun/fos, even c-myc, a transcription 
factor activated by the tyrosine kinase cascade, has been reported to regulate the 
PAI-1 gene (Prendergast 1990). 
Endotoxin (lipopolysaccharide - LPS) a component of the outer wall of Gram-
negative bacteria. LPS has been reported to have extensive biological effects, 
including increased production of PAI-1 in vivo (Colucci 1985, Sawdey 1991). The 
sensitivity reported for LPS varies remarkably between different experimental 
models. In vivo, LPS had an effect in the pg/ml range but, in vitro, when endothelial 
cells were used, the concentration had to be in the ug/ml range to be active. The in-
vivo concentrations correspond to the LPS sensitivity of cytokin-producing mono-
- 4 0 -
cytes (Müller 1993, Redl 1993). Consequently, the LPS effect in vivo on endothelium 
are probably indirect, and due to cytokin-producing immune-competent cells 
(Loskutoff 1991, Kruithof 1993). t-PA production has been reported to be decreased 
by LPS (Kooistra 1994, v Hinsbergh 1994). Cellular transduction of the LPS signal 
still remains to be clarified. Endotoxin has been reported to induce intracellular 
phosphorylation, PKC and Nuclear Factor-kappa-B activation (Nakano 1993, Hill 
1995, Thanos 1995). Several surface receptors have been proposed. Some of the 
receptors preferred to bind LPS in complex with the acute phase LPS-binding 
protein (Morrisson 1993). Serum requirement has also been reported in vitro and are 
probably a reason for low LPS reactivity in our experimental model (vd Berg 1988, 
Sawdey 1989). 
In the present study, endotoxin, in a serum-free medium, had no influence on the 
production of t-PA and PAI-1 from adult endothelium. However umbilical cells just 
reached the level of significantly increased t-PA and PAI-1 production, when the 
highest LPS concentration (10ug/ml) was added (papers II, III). LPS-increased t-PA 
and PAI-1 production were reduced when co-incubated with the PKC inhibitor H7 
(paper III). Similar results has been demonstrated by Nakano (Nakano 1993). Co-
incubating LPS with forskolin decreased PAI-1 production in both adult and umbilical 
cell. This data was in line with other reports, but might even be a direct non-LPS 
influenced effect of cAMP (Slivka 1991, Oilivier 1993). The effect of forskolin on LPS 
increased t-PA production diverged between the two types of cell, adult cells further 
increased and umbilical cell decreased their production (paper III). Taken together, 
these results indicated a PKC-dependent LPS pathway with cellorigin specific cAMP 
modulation. However, the reliability of these data when extrapolated to the in-vivo 
situation could be discussed. 
Thrombin the final enzyme in the coagulation cascade induces fibrin formation 
and pursues both positive and negative feedback on different coagulation factors. 
Further thrombin could enhance platelets activation and aggregation. Thrombin has 
also been demonstrated to cleave a short peptide from the N-terminus of a specific 
thrombin cell-surface receptor. The peptide could bind to and activate the receptor. 
When activated, the receptor molecule changes conformation, unmasking new intra­
cellular binding sites. The newly discovered receptor, belonging to the seven trans-
membrane-spanning receptor family, transducts signals through the GTP-binding 
protein system. When cleaved and activated, the receptor has to be re-placed and a 
state of desensitization occurs. Endothelium, in contrast to platelets, has a pool of 
new receptors that could be recruited from intracellular vesicles. The receptor-
binding capacity could also be modified by phosphorylation, and in analogy with the 
ß-adrenoceptor even protein kinase A could interact (v Obberghen-Schilling 1993, 
Wilhelm 1993, Brass 1995, Storck 1996). Following vascular injury, receptor expres­
sion is increased in vessel-wall smooth muscle cells, neointima (Runge 1995). 
In endothelium, thrombin signals have originally being described as transduced 
through the Gaq-protein pathway, which, in turn activates phospholipase C (PLC), 
diacylglycerol (DAG), Ca++ and protein kinase C (PKC) (Garcia 1992, Brass 1995). 
Recent research has demonstrated that, depending on the type of cell, the thrombin 
signal could dissociate several different types of Ga-proteins from their ßy-dimers. In 
endothelial cells, Gaj-protein has been reported to be activated by thrombin. Hypo-
thetically, the Gai / ßy-dimer pathway can influence adenylate cyclase, and the 
mitogen-activated protein (MAP) kinase cascade (Garcia 1992, v Obberghen-
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Schilling 1993, Brass 1995). In some types of cell, ßy-dimers have been found to 
increase the activity of specific PLC-isomers (Birnbauer 1992, Dickenson 1993). 
However, in human endothelium pertussis-toxin, inhibiting the Gai-pathway had no 
effect on thrombin-induced PLC activity, indicating the presence of ßy-dimer -
insensitive PLC-isomers (Garcia 1992). 
In the present study, thrombin increased the production of t-PA and PAI-1 both 
from umbilical and adult cells, the latter being the most reactive (papers 11-IV). This 
results were in line with other studies both in endothelium (Gelehrter 1986, Dichek 
1989, Grulich-Henn 1990). The PKC inhibitor H7 counteracted thrombin-increased 
production of t-PA and PAI-1, indicating the existence of the thrombin Gaq / PKC 
pathway (paper III), which corroborated data by others (Grulich-Henn 1990). When 
co-incubated with forskolin, adult cells reduced thrombin induction of t-PA and PAI-1 
production. These data were in line with a previous report (Francis 1989). On the 
other hand, umbilical cells demonstrated increased t-PA and unchanged PAI-1 
production. It has not been possible to rule out the mechanisms producing this 
diverging modulator effect of forskolin on adult and umbilical cells. A tentative theory 
is that different preferential pathways (Gai / Gaq) or a shift in the balance between 
stimulatory and inhibitory feedback mechanisms might be conceivable. 
Pertussis toxin (PTX) as a selective inhibitor of the Gai sub-group of GTP-
binding proteins has became a frequently used tool in transduction research (Hepler 
1992). 
In the present study (paper IV), PTX per se reduced basal PAI-1 but produced 
only minor attenuation of basal t-PA production. These results could be explained by 
the existence of a basal Gai-protein inhibitory tonus on adenylate cyclase, which 
corroborates other studies demonstrating reduced cAMP following PTX addition 
(Eguchi 1993, Manolopoulos 1995a). When thrombin was added to cells that had 
been preincubated with PTX, both the induction of t-PA and PAI-1 were decreased. 
The results indicated that thrombin signals were transducted through a Gai /ßy-
pathway. This was in agreement with reports demonstrating thrombin-induced 
stimulation of the MAP kinase cascade (Wheeler-Jones 1996, Chen 1996) but was at 
variance with the rapid PGI2 production being transducted trough the Gaq /PKC 
pathway (Garcia 1991). Studies exploring this pathway in t-PA and PAI-1 production 
seem to be rare. Pertussis toxin could add only marginal inhibition to forskolin, 
further decreasing thrombin-induced t-PA and PAI-1 production. This lack of additive 
effect could indicate that pertussis toxin and forskolin have an inhibitory influence on 
the same transduction pathway. 
Genistein, Vanadate. Transducting signals through a subsequent series of 
phosphorylating enzymes have been demonstrated to be one of the commonest 
mechanisms in cellular communication. The MAP or tyrosine kinase cascade could 
influence several different effectors, such as transcription factors, phospholipases, 
cytoskeletal and other regulatory proteins. This pathway could also be modulated by 
"cross-talk" to other signal transduction systems (Cobb 1991, Johnson 1994, 
Moolenaar 1995, Seger 1995). Genistein, a rather selective tyrosine kinase inhibitor, 
has been used extensively to block the transduction of signals in the MAP-kinase 
cascade (Akiyama 1991). The phosphorylating effect of kinases is balanced, in 
strength and duration, by phosphatases that de-phosphorylate the substrates. 
Multiple different enzymes, isomers and substrates exist and no simple ying and yan 
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relation between kinases and phosphatases has been reported (Hunter 1995). 
Sodium-ortho vanadate is a frequently used inhibitor of tyrosine-phosphatases. 
However, the intracellular substrates for vanadate are largely unknown, and 
disparate effects have been obtained in intact cell systems (Gordon 1991, Shimizu 
1994). 
In the present study, genistein reduced both basal and thrombin-stimulated t-PA 
and PAI-1 production. These results demonstrated that signals were transduced from 
the thrombin receptor to the MAP-kinase cascade. The data also proposed the 
existence of a basal tonus in the MAP cascade. Vanadate had no influence on basal 
t-PA or PAI-1 production. However, vanadate decreased thrombin-stimulated t-PA 
and PAI-1 secretion. The results indicated a phosphatase-dependent step in the 
thrombin transduction pathway. 
Genistein and even phosphatase inhibitors have recently been reported to inhibit 
the transduction of thrombin and other GTP-binding protein signals to the MAP 
cascade (Clark 1993, v Biesen 1995, Wheeler-Jones 1995, Chen 1996). In another 
study, cytokines activating tyrosine kinase receptors have been demonstrated to 
increase PAI-1 and u-PA but to decrease t-PA production from endothelial cells. 
Genistein reversed the effect of cytokines and reduced basal production. On the 
other hand, vanadate further increased cytokine induced production but had no effect 
on basal PAI-1 production (v Hinsbergh 1994). The differences between the present 
and the study of v Hinsbergh et al might be explained by the use of different 
agonists. Cytokine activates receptors at the top of the MAP cascade whereas 
thrombin signals are associated further down, probably at the adaptor protein She 
(Clark 1993, v Biesen 1995). The use of activating serum also diverged between the 
studies. 
This section has discussed the results in papers ll-IV, exploring the regulation of t-
PA and PAI-1 production from endothelial cells. In the following section, 
hypothesized signal transduction pathways based on the results in the present study 
and data from other cell systems will be presented. 
Hypothesized signal transduction pathways 
-in adult vein endothelial ceils 
See figure, with figures (1-7) corresponding to the text below. 
1) Thrombin, by signalling through its specific cell surface receptor, increased 
production of t-PA and PAI-1 from endothelial cells (papers ll-IV). The thrombin 
signal diverged already at the GTP-binding protein level, dissociating both Gaq and 
Gai from its ßy-dimers (Brass 1993, 1995, v Obberghen-Schilling 1993). 
2) The Gaq-pathway has been demonstrated to activate PLC and PKC, (Brass 
1993, 1995, v Obberghen-Schilling 1993). PMA, which induces long-lasting 
activation of PKC, increased both t-PA and PAI-1 production (Paper III). 
3) Thrombin-induced t-PA and PAI-1 could be reduced by pertussis toxin, 
indicating thrombin signalling through the Gai-pathway (Paper IV). 
4) Genistein, an inhibitor of MAP-kinase, reduced thrombin-increased t-PA and 
PAI-1 production. These results indicated that thrombin transducts signals through 
the MAP-kinase cascade (Paper IV). The phosphatase inhibitor, sodium ortho-
vanadate, had no effect on basal t-PA or PAI-1 production. However, vanadate could 
reduce thrombin-stimulated t-PA and PAI-1 production (data not published).These 
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data indicated the presence of a phosphatase-dependent step in the thrombin 
transduction pathway, corroborating data by Clark (Clark 1993). 
5) Forskolin, which increases intracellular cAMP, reduced basal PAI-1 production 
but had only minimal influence on basal t-PA production. Furthermore, forskolin also 
decreased PKC-induced PAI-1 production but stimulated PKC-induced t-PA 
production (Paper III). These data indicated that cAMP had an inhibitory effect on the 
transduction pathway: a) between PKC and the PAI-1 promotor, and b) between 
PKC and the receptor or on a parallel pathway regulating t-PA production. 
6) Forskolin/cAMP reduced thrombin-induced t-PA production but not PMA/PKC-
induced t-PA production. Reduction of the thrombin-effect was not influenced by 
preincubation with pertussis toxin (paper lll-IV). These data indicated that the 
decreasing effect of forskolin on thrombin-stimulated t-PA production did not act on 
the Gaq/PKC pathway, but probably on the Gai pertussis inhibiting pathway. The 
small GTP-binding protein, Ras, which activates Raf-1 in the MAP kinase cascade, 
has been reported to be inhibited by cAMP and could be a potential candidate for the 
observed forskolin-induced t-PA inhibition (Johnson 1994, Post 1996). Forskolin/ 
cAMP also reduced thrombin-induced PAI-1 production. As both basal and PMA-
induced PAI-1 production were inhibited by forskolin, it was not possible to construct 
a hypothesis concerning the Gaj-pathway inhibition of thrombin-induced PAI-1 
production. 
Thrombin 
MAP-kinase 
cascade 
ty-dimer 
Gaq-subunit Gaj-subunit 
adenylate cyclase Forskolin Phospholipase C 
Protein kinase C cAMP 
MAP-kinase 
t-PA / PAI-1 promotor 
SOS Grb2 ßy-dimer 
Genistein / Vanadate PTX 
Fig 16. Hypothesized signal transduction pathways, in adult vein endothelial 
cells. Figures (1-7) corresponding to the text in this section. The pathway from 
the thrombin ßy-dimer to the MAP kinase cascade is inserted as a magnification. 
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7) The signal transduction pathway from the thrombin-receptor to the MAP kinase 
cascade has not been completely described in endothelium. In other cell systems, 
ßy-dimers dissociated from Gai have been reported to activate Ras in the tyrosine 
kinase cascade (Corven 1993). Recently, the ßy-dimer has been demonstrated to 
activate proteins in the Src family. When activated, Src could phosphorylate the 
adaptor protein She. Activated She unmasks binding sites for the SH2 domain 
containing proteins as Ras and Grb2. When bound, Grb2 and the associated SOS 
protein are brought to the membrane where they could activate Ras. Both PH-
homology domains on the ßy-dimer and membrane lipids seem to be involved in the 
signal transduction (Bong 1995, v Biesen 1995, Bokoch 1996, Post 1996, Chen 
1996). 
Endothelial heterogeneity 
Cultured endothelial cells have been used extensively in in-vitro experiments. 
When data from different studies have to be compared it is important to realise that 
the results are dependent on the construction of the experimental model used. One 
of the most important factors in a cell model is the primary origin of the cells. Human 
umbilical vein endothelial cells have been frequently used to examine the regulation 
of t-PA arid PAI-1 production. Adult human endothelial vein cells have been used by 
some authors in an attempt to get closer to the clinical situation (v Hinsbergh 1987, 
Kooistra 1991, Haegerstrand 1992, Amman 1993). 
Endothelial heterogeneity.. 
Some characteristics are shared by all endothelial cells, e.g. production of the von 
Willebrand factor (Jaffe 1973b), prostacyclin, nitric oxide (Moncada 1990), 
expression of angiotensin-converting enzyme, VEGF-receptor and E-selektin (Risau 
1995). Other endothelial qualities demonstrate great inter-organ variation. In the 
literature there are several reports demonstrating endothelial organ heterogeneity: 
differences between species (Taylor 1987, Bartha 1988, v Hinsbergh 1988). 
differences between individuals of the same species (Levin 1984, v Hinsbergh 
1988, Chandler 1991). 
differences between anatomical locations (v Hinsbergh 1987, Taylor 1987, Wojta 
1989, Iba1991, Chandler 1992, Schrauwen 1994, Manolopoulos1993, 1995a,b) 
Qualitative differences 
Intracellular origin-heterogeneity. 
Hypothetical^, several intracellular levels could be of interest in an attempt to 
explain these differences. Heterogeneity has been described between: 
cells with different sets of GTP-binding proteins that could be dissociated by the 
receptor (Birnbauer 1992, Bernstein 1992, Hepler 1992). 
cells with different isoforms of intracellular enzymes such as adenyl cyclases 
(Iyengar 1993, Manolopoulos 1995), kinases (Johnson 1994, Nishizuka 1995) 
and lipases (Lee 1995, Roberts 1996). These different isoforms have both 
diverging regulatory and substrate-affinity patterns. 
cells with a different construction in their DNA-promotor regions. The rat t-PA 
promotor contains a CREB /cAMP responding element, whereas the human 
and mouse promotor in the corresponding position has a modified CRE-like 
sequence responding to AP-1/ PKC. Consequently, the rat, but not the human 
or mouse cells, increase their t-PA production when stimulated with cAMP 
(Medcalf 1990, Ohlsson 1992). 
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Externa! dynamic heterogeneity 
The characteristics to be expressed at a certain time by a specific cell are determined 
by several mechanisms. The state of cellular phenotype, being in dynamic interaction 
with the surrounding tissue, regulates the uncovering of genes (Pepper 1993, Risau 
1995, Edmondson 1996). 
External signals could regulate: 
receptor sensitivity (Hausdorff 1990, Brass 1995, Runge 1995), 
desensitization of intracellular transduction enzymes (Duniec 1990, Nishizuka 
1995) 
interactions between signal transduction pathways ("cross-talk") (Newman 1989, 
Garcia 1992, Johnson 1994, Bokoch 1996), 
prolonged stimulation could also affect the cellular synthesis of different GTP 
binding proteins and enzymes (Duniec 1990, Campell 1993, Eschenhaugen 
1992). 
Consequently, the incoming receptor signals could be interpreted in a variety of 
ways and evoke different responses depending on the type of cell or tissue. On the 
other hand, these differences might provide a tool for tissue-specific pharmacological 
modulations 
In the present study (paper III), qualitative differences in stimulated production of 
t-PA and PAI-1 were demonstrated between umbilical and adult endothelial cells. 
Forskolin-modulating PMA, LPS or thrombin-stimulated t-PA expression differently in 
umbilical and adult cells respectively. Thrombin signal transduction through Gaj-
protein and tyrosine kinase pathways has been explored both in adult cells (paper IV) 
and umbilical cells (not published), however, no differences could be detected. 
Quantitativ® differences 
The production of t-PA and PAI-1 from endothelial cells of different origin is a 
function of qualitative differences including cell origin, phenotype, preceding history 
and is also dependent on the state of ongoing stimulation. 
In this study (paper III), we presented quantitative differences, comparing the 
basal production of t-PA and PAI-1. Umbilical cells produced higher quantities of both 
t-PA and PAI-1 than adult cells. Differences have been demonstrated earlier. 
However, Amman (Amman 1993) presented higher t-PA production from adult, 
compared with umbilical cells. Furthermore, in paper IV we found PAI-1 levels in 
adult cells comparable with levels in umbilical cells in paper III. This discrepancy 
probably reflects the great quantitative variations between human endothelial cells of 
different origin in vitro (v Hinsbergh 1988) or between different individuals in vivo 
(Greén 1986, Chandler 1991). 
Thus, to present reliable results of quantitative differences between cells from 
different origins, data have to be collected from a large number of cultures 
representing different individual veins. 
Summary 
There is still no consensus about the type of cell to be used in vascular in-vitro 
experiments. As endothelial cells from different origins in the body have proved to be 
quite heterogeneous it cannot be presumed that cells from only one of these origins 
could be representative of all types of vessels. Even if a great deal of data could be 
generalized, the cell type being the most relevant for an in-vitro experiment, depends 
on the vascular segment of clinical interest. Furthermore, it is very important to keep 
the experimental conditions identical throughout an experimental series in order to be 
able to compare the results. 
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SUMMARY 
The main experimental findings were: 
1. The production of prostacyclin from endothelial cells was increased by the 
adrenergic agonist isoprenalin, 
2. The ß-adrenoceptor blockers, propranolol or metoprolol, synergistically increased 
endothelial prostacyclin production when co-incubated with isoprenalin. 
Propranolol or metoprolol per se had no effect. 
3. The production of tissue plasminogen activator (t-PA) from umbilical and adult 
endothelial cells was increased by phorbolester and thrombin. In high 
concentrations, endotoxin increased the production from umbilical but not from 
adult cells. Forskolin, isoprenalin, ephedrine, Na-nitroprusside or endothelin-1 had 
no influence on the production of t-PA. 
4. The production of plasminogen activator inhibitor type-1 (PAI-1) from umbilical and 
adult endothelial cells was increased by phorbolester and thrombin. In high 
concentrations, endotoxin increased the production from umbilical but not from 
adult cells. Forskolin decreased PAI-1 production. Isoprenalin, ephedrine or 
endothelin-1 had no influence on the production of PAI-1. Na-nitroprusside had a 
weak increasing effect. 
5. The protein kinase C inhibitor H7 decreased t-PA and PAI-1 production which had 
been induced by endotoxin, thrombin or phorbolester in both umbilical and adult 
cells. 
6. Forskolin decreased PAI-1 production which had been induced by endotoxin, 
thrombin and phorbolester both in umbilical and adult cells. 
On the other hand, the effect on t-PA production diverged between cells of 
different origin when endotoxin, thrombin or phorbolester were co-incubated with 
forskolin. 
7. Thrombin-induced tissue plasminogen activator (t-PA) and plasminogen activator 
inhibitor type-1 (PAI-1) production from adult endothelial cells were decreased by 
pertussis toxin or genistein, representing Gaj-protein and tyrosine kinase pathway 
inhibitors respectively. 
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CONCLUSIONS 
1. The production of prostacyclin from endothelial cells is under adrenergic control, 
modulating the effect of ß-adrenoceptor blockers. 
2. Signal transduction through adenylate cyclase, protein kinase C, Gw j-protein and 
tyrosine kinase pathways is critical in the regulation of t-PA and PAI-1 production 
from endothelial cells. 
3. Interference with adenylate cyclase could be one way of modulating the balance 
between coagulation and fibrinolysis in the vessel. 
4. Endothelial cells of different origin regulate the production of tissue plasminogen 
activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) differently. 
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